A Pilot Electroencephalography (EEG) Study to Evaluate the Effect of CT1812 Treatment on Synaptic Activity in Subjects With Mild to Moderate Alzheimer's Disease
Phase: PHASE2
Conditions: Alzheimer Disease
Sponsor: Cognition Therapeutics

Main Title 
A Pilot Electroencephalography (EEG) Study to Evaluate the Effect of CT1812 Treatment on 
Synaptic Activity in Subjects With Mild to Moderate Alzheimer’s Disease 
Protocol Number: COG0202 
Official Short Title: 
Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer’s Disease Using EEG 
Clinical Study Protocol 
FINAL Version 4.0 
Date:  February 21, 2022 
EUDRACT NUMBER 
2019-003552-36 
Confidentiality Statement: 
This document contains information proprietary to Cognition Therapeutics, Inc. and is intended 
solely for the purpose of this clinical investigation. It should be kept securely and its contents 
should not be disclosed to any third party without the prior written consent of Cognition 
Therapeutics, Inc. 

23Feb2022

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 3 of 93 
EudraCT: 2019-003552-36 
 
SIGNATURE PAGE FOR INVESTIGATOR 
 
Study No.  
 
COG0202 
 
Protocol Title:  
A Pilot Electroencephalography (EEG) Study to Evaluate the Effect of 
CT1812 Treatment on Synaptic Activity in Subjects With Mild to Moderate 
Alzheimer’s Disease 
 
I have read this protocol and agree to conduct this study in accordance with all stipulations of 
the protocol and in accordance with all applicable regulations, including the International 
Conference on Harmonisation (ICH) Tripartite Guideline for Good Clinical Practice (GCP), and 
the Guidelines of the Declaration of Helsinki. 
 
 
 
 
 
 
 
 
Investigator Name
Signature
Date
 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 4 of 93 
EudraCT: 2019-003552-36 
 
1 
STUDY ORGANIZATIONAL STRUCTURE 
 
Sponsor: 
Cognition Therapeutics, Inc. 
Medical Director 
 
Chief Medical Officer 
Cognition Therapeutics, Inc. 
2500 Westchester Avenue 
Purchase, NY 10577 
Primary Sponsor Contact 
 
Clinical Operations Lead 
 
 Clinical Operations 
Cognition Therapeutics, Inc. 
2500 Westchester Avenue 
Purchase, NY 10577 
 
 
24-Hour Medical Monitor Coverage 
 
Cognition Therapeutics, Inc. 
2500 Westchester Avenue 
Purchase, NY 10577 
 
  
 
 
 
 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 5 of 93 
EudraCT: 2019-003552-36 
 
2 
PROTOCOL SYNOPSIS  
TITLE:  
A Pilot Electroencephalography (EEG) Study to Evaluate the Effect of CT1812 
Treatment on Synaptic Activity in Subjects With Mild to Moderate Alzheimer’s 
Disease  
SPONSOR:  
Cognition Therapeutics, Inc. 
PROTOCOL NUMBER:  
COG0202 
CLINICAL STUDY PHASE: 
2 
STUDY DRUG PRODUCT: 
CT1812 
STUDY OBJECTIVES:  
Primary: 
 
To evaluate the safety, tolerability, and pharmacokinetics (PK) of CT1812 following 
repeated dosing of CT1812 for 29 days. 
 
To evaluate the efficacy of CT1812 in restoring synaptic function in participants with 
mild to moderate Alzheimer’s disease (AD) through quantitative EEG measurements, 
as reflected by relative theta power. 
Exploratory: Cerebrospinal fluid 
 
Measure changes in exploratory cerebrospinal fluid (CSF) and plasma biomarkers, 
including synaptic damage biomarkers such as neurogranin, measured at baseline 
and through the end of each treatment period. 
 
To evaluate changes in cognitive and global functioning, as measured by the 
following:  
o Alzheimer’s Disease Assessment Scale–cognitive subscale (ADAS-Cog-14). 
o Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change 
(ADCS-CGIC). 
o Amsterdam Instrumental Activity of Daily Living Questionnaire (A-IADL-Q). 
o Neuropsychological test battery (NTB) that includes Category Fluency Test 
(CFT), Controlled Word Association Test (COWAT), Trail Making Test (TMT) 
Parts A & B, and Wechsler Memory Digit Span (VMDS). 
o Evaluate additional quantitative EEG measures that have shown promise as 
diagnostic/treatment marker: relative alpha (8-13 Hz) and beta (13-30 Hz) 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 6 of 93 
EudraCT: 2019-003552-36 
 
power, theta/alpha power ratio, spectral peak frequency, and functional 
connectivity measures corrected Amplitude Envelope Correlation (AEC-c). 
STUDY DESIGN: 
This is a single-site, randomized, double-blind, placebo-controlled, 29-day, 2-period 
crossover Phase 2 study of 1 dose level of CT1812 (active) or placebo in adults with mild 
to moderate AD.  
Screening procedures will occur on Days -42 to -1. Eligible participants will return to the 
study site at the Baseline/Day 1 visit and will be randomly assigned to either active study 
drug or placebo. Participants will return home and will take study treatment daily for 
4 weeks (Day 1 through Day 29), followed by a 2-week washout period. Afterwards, 
participants will return to the study site to receive the crossover treatment (placebo or 
active) for the second treatment period of 29 days (Days 44 to 72). Participants will return 
to the study site 12 days after the final dose of study treatment for follow-up safety and 
laboratory assessments. The total duration of participant participation in the study, 
including the screening period, is up to 126 days. (For a detailed list of assessments, see 
Table 1: Schedule of Assessments.) 
NUMBER OF PARTICIPANTS: 
16 participants (8 randomized to 300 mg CT1812, 8 randomly assigned to placebo during 
each treatment period): the 8 participants randomly assigned to CT1812 in Treatment 
Period 1 will receive placebo in Treatment Period 2; the 8 participants randomly assigned 
to placebo in Treatment Period 1 will receive CT1812 in Treatment Period 2.  

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 7 of 93 
EudraCT: 2019-003552-36 
 
TARGET POPULATION: 
 
INCLUSION CRITERIA: 
Participants may be included in the study only if they meet all the following criteria: 
1) Women of non-childbearing potential and men, aged 50 to 85 years, inclusive, with a 
diagnosis of mild to moderate Probable Alzheimer’s Disease Dementia, according to 
the NIA-AA 2018 criteria and at least a 6-month history of decline in cognitive function 
documented in the medical record. 
i) 
Non-childbearing potential for women is defined as postmenopausal (last 
menses greater than 24 months) or undergone a documented bilateral tubal 
ligation or hysterectomy. If last menses less than 24 months, a serum follicle 
stimulating hormone (FSH) confirming post-menopausal status will be 
determined. 
ii) Male participants who are sexually active with a woman of child-bearing 
potential must agree to use condoms during the study and for 3 months after 
last dose. Female partners should also consider using an acceptable means of 
birth control, though it is not mandatory. Acceptable forms of birth control 
include abstinence, birth control pills, or any double combination of: 
intrauterine device (IUD), male or female condom, diaphragm, sponge, and 
cervical cap. 
2) CSF meets CSF abeta 1‐42 (abeta) and p-tau -181 criteria as defined below.  
 
CSF abeta 1‐42 < 1000pg/ml (Elecsys assay) AND 
CSF p‐tau 181 > 19 pg/ml (Elecsys Assay) 
 
OR:   
CSF abeta 1‐42 < 1000pg/ml (Elecsys assay) AND 
p‐tau ‐181 / abeta 1‐42 ratio > 0.020 
 
OR: 
CSF p‐tau 181 > 19 pg/ml (Elcsys Assay) AND 
p‐tau ‐181 / abeta 1‐42 ratio > 0.020 
 
Historical CSF results will be considered provided the results are consistent with the 
CSF thresholds required for inclusion and following discussion with the medical 
monitor; however, a lumbar puncture is still required as part of screening procedures. 
3) Neuroimaging (MRI) consistent with the clinical diagnosis of Alzheimer’s disease and 
without findings of significant exclusionary abnormalities (see exclusion criteria, 
number 4). A historical MRI, up to 1 year prior to screening, may be used as long as 
there have been no interval clinical neurologic events which may suggest a change in 
the MRI scan. 
4) MMSE score of 18 to 26, inclusive. 
5) No active depression and a GDS ≤ 6 (see exclusion criteria number 6). 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 8 of 93 
EudraCT: 2019-003552-36 
 
6) Formal education of 8 or more years. 
7) Participants must have a caregiver/ study partner who in the opinion of the site’s 
Principal Investigator, has contact with the study participant for a sufficient number of 
hours per week to provide informative responses on the protocol assessments, 
oversee the administration of study drug, and is willing and able to participate in all 
study site visits and some study assessments. The caregiver/study partner must 
provide written informed consent to participate in the study.  
8) Participants living at home or in the community (assisted living acceptable). 
9) Participants must have no known history of difficulty swallowing capsules. 
10) Stable pharmacological treatment of any other chronic conditions for at least 30 days 
prior to screening. 
11) Must consent to apolipoprotein E (APOE) genotyping. 
12) Participants shall be generally healthy with mobility (ambulatory or ambulatory-aided, 
i.e., walker or cane), vision and hearing (hearing aid permissible) sufficient for 
compliance with testing procedures. 
13) Must be able to complete all screening evaluations. 
 
EXCLUSION CRITERIA: 
Participants will be excluded from the study if any of the following conditions apply: 
1) Hospitalization (except for planned procedures) or change of chronic concomitant 
medication within 1 month prior to screening. 
2) Participants living in a continuous care nursing facility. 
3) Contraindications to the MRI examination for any reason. 
4) MRI of the brain indicative of significant abnormality, including, but not limited to, prior 
hemorrhage or infarct > 1 cm3, > 3 lacunar infarcts, cerebral contusion, 
encephalomalacia, aneurysm, vascular malformation, subdural hematoma, 
hydrocephalus, space-occupying lesion (e.g., abscess or brain tumor such as 
meningioma). Small incidental meningiomas may be allowed if discussed and 
approved by the Medical Monitor. 
5) Clinical or laboratory findings consistent with: 
a) Other primary degenerative dementia, (dementia with Lewy bodies, 
fronto-temporal dementia, Huntington’s disease, Creutzfeldt-Jakob Disease, Down 
syndrome, etc.). 
b) Other neurodegenerative condition (Parkinson’s disease, amyotrophic lateral 
sclerosis, etc.). 
c) Seizure disorder. 
d) Other infectious, metabolic or systemic diseases affecting the central nervous 
system (syphilis, present hypothyroidism, present vitamin B12 or folate deficiency, 
other laboratory values etc.). 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 9 of 93 
EudraCT: 2019-003552-36 
 
6) A current DSM-V diagnosis of active major depression, schizophrenia or bipolar 
disorder. Participants with depressive symptoms successfully managed by a stable 
dose of an antidepressant are permitted. 
7) Clinically significant, advanced or unstable disease that may interfere with outcome 
evaluations, such as: 
a) Chronic liver disease, liver function test abnormalities or other signs of hepatic 
insufficiency (ALT, AST, alkaline phosphatase > 1.5 ULN, lactate dehydrogenase 
(LDH) > 1.5 x ULN). 
b) Respiratory insufficiency. 
c) Renal insufficiency eGFR < 50 mL/min based on the CKD‐EPI Creatinine formula, 
https://www.mdcalc.com/ckd-epi-equations-glomerular-filtration-rate-gfr. 
d) Heart disease (myocardial infarction, unstable angina, heart failure, 
cardiomyopathy within 6 months before screening). 
e) Bradycardia (< 50/min.) or tachycardia (> 100/min.). 
f) Poorly managed hypertension (systolic > 160 mm Hg and/or diastolic > 95 mm 
Hg) or hypotension (systolic < 90 mm Hg and/or diastolic < 60 mm Hg). 
g) Uncontrolled diabetes in known diabetics, as defined by hemoglobin A1c (HbA1c) 
> 7.5. 
8) History of cancer within 3 years of screening with the exception of fully excised non-
melanoma skin cancers or non-metastatic prostate cancer that has been stable for at 
least 6 months. 
9) Seropositive for human immunodeficiency virus (HIV). 
10) History of acute/chronic hepatitis B or C and/or carriers of hepatitis B (seropositive for 
hepatitis B surface antigen [HbsAg] or anti-hepatitis C virus [HCV] antibody). 
11) Clinically significant abnormalities in screening laboratory tests, including:  
a) Hematocrit less than 35% for males and less than 32% for females, absolute 
neutrophil cell count of <1500/uL (with the exception of a documented history of a 
chronic benign neutropenia), or platelet cell count of < 120,000/uL; international 
normalized ratio (INR) > 1.4 or other coagulopathy, confirmed by repeat 
assessment of: 
i) 
Hematocrit. 
ii) Neutrophil count. 
iii) Platelet count. 
12) Disability that may prevent the participant from completing all study requirements 
(e.g., blindness, deafness, severe language difficulty, etc.). 
13) Within 4 weeks of screening visit or during the study, concurrent treatment with 
antipsychotic agents, antiepileptics, centrally active anti-hypertensive drugs (e.g., 
clonidine, l-methyl dopa, guanidine, guanfacine, etc.), sedatives, opioids, mood 
stabilizers (e.g., valproate, lithium); or benzodiazepines. 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 10 of 93 
EudraCT: 2019-003552-36 
 
14) Any disorder that could interfere with the absorption, distribution, metabolism or 
excretion of drugs (e.g., small bowel disease, Crohn’s disease, celiac disease, or liver 
disease). 
15) Nootropic drugs, except AD medication (acetylcholinesterase inhibitors and 
memantine) that the participant should have been taking for no less than 3 months. 
New medications, including AD medication, should not be started during the study 
without consultation with the Medical Monitor. 
16) Suspected or known drug or alcohol abuse, i.e., more than approximately 60 g alcohol 
(approximately 1 liter of beer or 0.5 liter of wine) per day. 
17) Suspected or known allergy to any components of the study treatments. 
18) Enrollment in another investigational study or intake of investigational drug within the 
previous 30 days or 5 half-lives of the investigational drug, whichever is longer. 
19) Intake of drugs or substances potentially involved in clinically significant induction or 
inhibition of cytochrome P450 3A4 (CYP3A4) or P-glycoprotein (P-gp) mediated drug 
interactions with CT1812, within 4 weeks or 5 half-lives of the interacting drug prior to 
administration of CT1812 and throughout the study. Grapefruit juice should be 
avoided in the 2 weeks prior to dosing and throughout the study. See Appendix A for a 
complete list of prohibited substances. 
20) Exposure to immunomodulators, anti Aβ vaccines, passive immunotherapies for AD 
(e.g., monoclonal antibodies) within the past 180 days and/or exposure to beta 
secretase cleaving enzyme (BACE) inhibitors within the past 30 days. 
21) Anticipated use of nonsteroidal anti-inflammatory drugs (NSAIDs) on more than 
14 days during the study period. 
22) Contraindication to undergoing lumbar puncture (LP) including, but not limited to: 
inability to tolerate an appropriately flexed position for the time necessary to perform 
an LP; INR > 1.4 or other coagulopathy; platelet count of < 120,000/μL; infection at 
the desired LP site; taking anti-coagulant medication within 90 days of screening 
(low-dose aspirin is permitted); degenerative arthritis of the lumbar spine; suspected 
non-communicating hydrocephalus or intracranial mass; and, prior history of spinal 
mass or trauma. 
23) Any condition, which in the opinion of the Investigator or the Sponsor makes the 
participant unsuitable for inclusion. 
LENGTH OF STUDY: 
Participants will be screened up to 42 days prior to the Baseline/Day 1 visit. Each 
participant will receive active drug and placebo during this crossover study. The first 
treatment period (29 days) will be followed by a 14-day washout. Immediately after the 
washout, there will be a second treatment period for 29 days, followed by a 12-day safety 
follow-up period. Total planned duration is up to 126 ± 2 days, including the up to 42-day 
screening period. 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 11 of 93 
EudraCT: 2019-003552-36 
 
DOSAGE, DOSE FORM, AND ROUTE OF ADMINISTRATION: 
CT1812 will be dosed at 300 mg/day for the active dose level.  
CT1812 will be provided to participants as two hydroxypropyl methylcellulose (HPMC) 
capsules each containing 150 mg of CT1812. Matching placebo capsules will be 
provided. Study drug will be supplied in appropriately labeled bottles. 
CT1812 will be administered orally. 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 12 of 93 
EudraCT: 2019-003552-36 
 
EVALUATION CRITERIA: 
Safety will be assessed via the monitoring of  
 
Adverse events. 
 
Physical examinations. 
 
Vital signs - BP, heart rate and body temperature. 
 
Electrocardiogram (ECG).  
 
Clinical laboratory tests:  
o Blood chemistry  
o Hematology 
o Urinalysis  
o Plasma.  
 
Affective and cognitive measures:  
o Columbia Suicide Severity Rating Scale (C-SSRS). 
o ADAS-Cog-14, ADCS-CGIC, A-IADL-Q, and an NTB that includes CFT, 
COWAT, TMT Parts A & B, and VMDS. 
Pharmacokinetic assessments include: 
 
Serum CT1812 concentrations at specified timepoint. (See Table 1 – Schedule of 
Assessments). 
 
CSF: concentration of CT1812 at trough (24-hour postdose). 
Pharmacodynamics assessments include: 
 
Analyses of plasma and CSF for biomarkers of target engagement or disease 
modification. 
STATISTICAL CONSIDERATIONS: 
Sample size justification: 
For the endpoint of global relative theta power (the fraction of the total brain activity 
accounted for by theta wave frequency), the assumed within-subject standard deviation 
(SD) is equal to 3%. Based on the use of a two-sided one-sample (within-subject) 
comparison between CT1812 and placebo at the alpha=0.05 level of significance, a sample 
size of 16 participants provides 90% power to detect a mean difference between treatments 
of 2.5%. 
For the endpoint of CSF neurogranin assuming a true within-subject SD of 129.6 pg/mL 
and based on the use of a two-sided one-sample comparison at the alpha=0.05 level of 
significance, a sample size of 16 participants provides 90% power to detect a treatment 
difference of -105 pg/mL. 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 13 of 93 
EudraCT: 2019-003552-36 
 
Safety analyses: 
 
AEs will be assessed by the Investigator for severity and will be coded for summarization 
using Medical Dictionary for Regulatory Activities (MedDRA® Version 22). Concomitant 
medications will be coded using WHO Drug Dictionary (enhanced) WHODrug Global (B3) 
2019 Mar 1. 
Adverse events (AEs) will be summarized by Medical Subject Headings (MeSH) Term 
and System, for each dose group (including placebo) and the incidence compared. 
Laboratory measures will be summarized by treatment group and timepoint, both as 
absolute values and as change from baseline, with descriptive statistics summarizing 
each group and timepoint. Similar presentations will be used for vital signs, ECG interval 
measurements, and changes from pre-treatment baseline. 
Analyses of PK parameters and pharmacodynamics markers: 
Standard non-parametric statistical analyses will be used to examine the relationships 
between dose and PK parameters. 
Pharmacodynamics markers in CSF and CT1812 concentrations in serum and CSF will 
be summarized using appropriate descriptive statistics. 
Additional statistical details will be provided in a prospective statistical plan. 
Safety Stopping Rules  
 
For all participants 
The occurrence of any one of the following events will result in suspension of 
administration of study drug in all participants until safety information can be further 
reviewed by the Sponsor and Medical Monitor. 
 
Two occurrences of the same or similar serious adverse events (SAEs) assessed 
as probably or possibly related to dosing with investigational product  
 
Two or more different participants with the same or similar severe AE assessed as 
probably or possibly related to dosing with the investigational product 
 
Four or more participants with the same or similar moderate AE which is possibly 
or probably related to dosing with investigational product. 
 
Under these circumstances, the Sponsor and Medical Monitor will review the available 
safety data and, in consultation with the site’s Principal Investigator, recommend whether 
dosing should continue, or if study drug administration should be terminated, or if 
additional monitoring procedures or safety precautions need to be employed.  
If a stopping rule is achieved, selective unblinding of the participants involved may be 
performed by the Sponsor to determine if the SAEs/AEs are isolated to a single dose 
group or if they occurred in placebo participants.  

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 14 of 93 
EudraCT: 2019-003552-36 
 
The study or a dose group may also be terminated if the Medical Monitor, Study Director 
and Sponsor, in consultation with the site’s Principal Investigator, determine if any AEs 
have occurred that are intolerable or pose a medically unacceptable safety risk. 
 
For individual participants 
Participants who develop a severe AE or laboratory abnormality will not receive any 
additional doses and will be monitored until resolution of the AE or the return of laboratory 
abnormality to the acceptable screening value(s). Study drug may be re-initiated after 
consultation with Medical Monitor and Sponsor. Any participant with: 
 
Elevated ALT or AST greater than 5 X ULN should have dosing with study drug 
stopped and have laboratory tests repeated every 3-4 days until levels return to 
less than or equal to 1.5 X ULN. If the Medical Monitor and Investigator are in 
agreement, study drug may be continued while a confirmatory ALT/AST is 
obtained within 3 days. If the confirmatory ALT/AST tests are below 5 X ULN, 
study drug may be continued. The frequency of the laboratory tests may be 
modified after discussion with the Medical Monitor if the liver enzymes are in a 
decreasing trend.  
 
Elevated ALT or AST greater than 3 X ULN in combination with total bilirubin 
> 2 X ULN or INR > 1.5 X ULN OR an ALT or AST > 3 X ULN with the appearance 
of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, 
and/or eosinophilia (> 5%) should have dosing with study drug stopped and have 
laboratory testing repeated every 3 to 4 days. If the Medical Monitor and 
Investigator are in agreement, study drug may be continued while a confirmatory 
laboratory testing is obtained within 3 days. If these criteria are no longer met, 
study drug can be continued at the discretion of the Medical Monitor and 
Investigator. The frequency of the laboratory tests may be modified after 
discussion with the Medical Monitor if the laboratory tests are trending towards 
normal.  
 
An increase in serum creatinine by 0.3 mg/dL (24.4 micromol/L) or 150% of 
baseline, which is without clinical explanation of another etiology, will result in 
repeated serum chemistry testing within 3 to 7 days. If the serum creatinine 
elevation is confirmed on repeated testing the study drug will be discontinued. If 
the serum creatinine elevation resolves upon subsequent testing after study drug 
is discontinued the study drug may be restarted with serum creatinine monitoring 
at the discretion of the Medical Monitor and Investigator. 
 
An increase in serum calcium to ≥10.5 mg/dl (2.63 mmol/L), which is 
without clinical explanation of another etiology, will result in repeated 
serum chemistry testing within 3-7 days. If the serum calcium elevation is 
confirmed on repeated testing the study drug will be discontinued. If the serum 
calcium elevation resolves upon subsequent testing after study drug is 
discontinued the study drug may be restarted with serum calcium monitoring at the 
discretion of the Medical Monitor and Investigator. 
 
Note: Fractional excretion of calcium will be monitored in each participant and 
interpreted in conjunction with serum creatinine and serum calcium. Given 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 15 of 93 
EudraCT: 2019-003552-36 
 
the ability of fractional excretion to fluctuate, no upper limit for discontinuing study 
drug based on fractional excretion of calcium has been set but it may be used as a 
stopping rule if persistent unexplained increases in fractional excretion of calcium 
are observed. 
 
 
 
 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 16 of 93 
EudraCT: 2019-003552-36 
 
Table of Contents 
 
1 
Study Organizational Structure ............................................................................................ 4 
2 
Protocol Synopsis ................................................................................................................ 5 
3 
Glossary of Terms and Abbreviations .................................................................................20 
4 
Introduction .........................................................................................................................24 
4.1 
Background.................................................................................................................24 
4.2 
Nonclinical Experience ................................................................................................26 
4.2.1 Nonclinical Pharmacology Studies...........................................................................26 
4.2.2 Nonclinical Pharmacokinetic Studies .......................................................................27 
4.2.3 Nonclinical Safety Studies .......................................................................................28 
4.3 
Clinical Experience .....................................................................................................29 
4.4 
Rationale for Study .....................................................................................................31 
4.4.1 Rationale for Selected Dose ....................................................................................31 
5 
Study Objectives .................................................................................................................31 
5.1 
Primary .......................................................................................................................31 
5.2 
Exploratory .................................................................................................................32 
6 
Study Type and Design ......................................................................................................32 
6.1 
Study Type .................................................................................................................32 
6.2 
Endpoints ....................................................................................................................32 
6.2.1 Exploratory Efficacy Endpoints ................................................................................32 
6.2.2 Safety Endpoints .....................................................................................................33 
6.2.3 Pharmacokinetic/Pharmacodynamic Endpoints .......................................................33 
6.3 
Study Design ..............................................................................................................33 
7 
Study Drug .........................................................................................................................34 
7.1 
Supply and Storage ....................................................................................................34 
7.2 
Packaging and Labeling ..............................................................................................34 
7.3 
Administration .............................................................................................................35 
7.3.1 Safety Stopping Rules .............................................................................................35 
7.4 
Drug Accountability .....................................................................................................37 
7.5 
Overdose/Toxicity Management ..................................................................................38 
7.6 
Blinding, Randomization, and Matching Participants ...................................................38 
8 
Investigators, Sites and Duration ........................................................................................38 
8.1 
Investigator and Study Site .........................................................................................38 
8.2 
Duration of Study ........................................................................................................38 
8.3 
Termination of Study ...................................................................................................39 
9 
Study Population ................................................................................................................39 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 17 of 93 
EudraCT: 2019-003552-36 
 
9.1 
Number of Participants ...............................................................................................39 
9.2 
Inclusion Criteria .........................................................................................................39 
9.3 
Exclusion Criteria ........................................................................................................41 
9.4 
Withdrawal of Participants ...........................................................................................44 
9.5 
Participant Withdrawal Procedures .............................................................................44 
9.5.1 Follow-up Procedures for Participants Who Withdraw Prematurely .........................44 
9.6 
Procedures for Replacing Participants Who Withdraw Prematurely ............................44 
10 
Treatment Plan and Methods .........................................................................................45 
10.1 
Schedule of Assessments ...........................................................................................45 
10.2 
Visit Specific Procedures ............................................................................................49 
10.2.1 Visit 1 / Screening ...................................................................................................49 
10.2.2 Visit 2 / Study Day 1 – Baseline ...............................................................................50 
10.2.3 Visit 3 / Study Day 3 – Telephone Wellness Check .................................................51 
10.2.4 Visit 4 / Study Day 8 ................................................................................................52 
10.2.5 Visit 5 / Study Day 15 ..............................................................................................52 
10.2.6 Visit 6 / Study Day 22 ..............................................................................................53 
10.2.7 Visit 7 / Study Day 29 (+/- 2 days) ...........................................................................54 
10.2.8 Days 30 to 43 – Washout Period .............................................................................55 
10.2.9 Visit 8 / Study Day 44 ..............................................................................................55 
10.2.10 Visit 9 / Study Day 46 – Telephone Wellness Check ............................................. 56 
10.2.11 Visit 10 / Study Day 51 .......................................................................................... 56 
10.2.12 Visit 11 / Study Day 58 …………………………………………………………………. 57 
10.2.13 Visit 12 / Study Day 65 .......................................................................................... 58 
10.2.1  Visit 13 / Study Day 72 (+/- 2 days) ........................................................................ 59 
10.2.15 Visit 14 / Study Day 84 / End-of-Study Visit .......................................................... 60 
10.3 
Concomitant Medications and Other Restrictions ........................................................60 
11 
Sample Collection ..........................................................................................................61 
11.1 
Volume of Blood Collected ..........................................................................................61 
11.2 
Blood Sampling for PK and Exploratory Biomarkers ...................................................61 
11.3 
Handling, Shipping, Storage, and Analysis of Blood Samples .....................................61 
11.3.1 Samples for Future Biomedical Research (FBR) .....................................................61 
11.4 
Pharmacokinetic Endpoints .........................................................................................63 
11.5 
Cerebrospinal Fluid .....................................................................................................63 
11.5.1 Collection ................................................................................................................63 
11.5.2 Timing of CSF Collection .........................................................................................64 
11.5.3 Volume of CSF Collected ........................................................................................64 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 18 of 93 
EudraCT: 2019-003552-36 
 
11.5.4 Handling, Shipping, Storage and Analysis of CSF ...................................................64 
12 
Efficacy Assessments .....................................................................................................64 
12.1 
Affective and Cognitive Measures ...............................................................................64 
12.1.1 Alzheimer's Disease Assessment Scale-cognitive subscale ....................................64 
12.1.2 Geriatric Depression Scale ......................................................................................64 
12.1.3 Mini-Mental State Exam ..........................................................................................65 
12.1.4 Neuropsychological Test Battery (NTB) ...................................................................65 
12.1.5 Alzheimer’s Disease Cooperative Study -Clinical Global Impression of Change ......65 
12.1.6 Amsterdam Instrumental Activity of Daily Living Questionnaire ...............................65 
12.2. Other: Pharmacodynamic Assessments........................................................................66 
12.2 
EEG Recordings .........................................................................................................66 
13 
Safety Assessments .......................................................................................................66 
13.1.1 Safety Oversight ......................................................................................................66 
13.1.2 Adverse Events .......................................................................................................66 
13.1.3 Physical Examination ..............................................................................................67 
13.1.4 Vital Signs ...............................................................................................................67 
13.1.5 Clinical Laboratory Tests .........................................................................................67 
13.1.6 Acute Kidney Injury Biomarker Testing ....................................................................68 
13.1.7 Columbia Suicide Severity Rating Scale ..................................................................69 
13.1.8 12-lead Electrocardiogram ......................................................................................69 
13.1.9 MRI .........................................................................................................................69 
13.2 
Adverse Events ...........................................................................................................70 
13.2.1 Definitions ...............................................................................................................70 
13.2.2 Collection and Rating of Adverse Events .................................................................71 
13.2.3 Adverse Event Follow-up .........................................................................................73 
14 
Serious and Other Significant Adverse Events ...............................................................74 
14.1.1 Definition of a Serious Adverse Event .....................................................................74 
14.1.2 Serious Adverse Event Reporting by the Investigator to the Sponsor ......................75 
14.1.3 Handling of Follow-up Information ...........................................................................76 
14.1.4 Reporting and Follow-up of Pregnancy ....................................................................76 
14.1.5 Expedited Reporting of Serious Adverse Events .....................................................77 
15 
Statistical Methods .........................................................................................................78 
15.1 
General Overview of the Statistical Analysis Plan .......................................................78 
15.2 
Sample Size Justification ............................................................................................78 
15.3 
Analysis Populations ...................................................................................................78 
15.4 
Data Analysis ..............................................................................................................78 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 19 of 93 
EudraCT: 2019-003552-36 
 
15.5 
Missing, Unused and Spurious Data ...........................................................................80 
16 
Study Management ........................................................................................................80 
16.1 
Protocol Amendment and Protocol Deviation ..............................................................80 
16.1.1 Protocol Amendment ...............................................................................................80 
16.1.2 Protocol Deviations .................................................................................................80 
16.1.3 Protocol Waivers .....................................................................................................81 
16.2 
Ethics and Regulatory Aspects ...................................................................................81 
16.2.1 Ethical Conduct of the Study and Regulatory Guidelines .........................................81 
16.2.2 Institutional Review Board and Regulatory Approval ...............................................81 
16.2.3 Participant and Study Partner Informed Consent .....................................................81 
16.3 
End of Study and Regulatory Notification ....................................................................82 
16.4 
Data Protection and Confidentiality .............................................................................83 
16.5 
Monitoring ...................................................................................................................83 
16.6 
Quality Assurance and Quality Control ........................................................................83 
16.7 
Source Data ................................................................................................................84 
17 
Data and Record Keeping ..............................................................................................84 
17.1 
Case Report Forms .....................................................................................................84 
17.2 
Record Keeping ..........................................................................................................85 
18 
Financing and Insurance ................................................................................................85 
19 
Use of Data and Publication Policy .................................................................................86 
20 
References .....................................................................................................................87 
21 
APPENDICES ................................................................................................................91 
 
 
 
 
List of Tables 
 
 
Table 1 – Schedule of Assessments .........................................................................................45 
 
 
List of Appendices 
 
Appendix A – Prohibited Medications - Cytochrome P450 Drug Interaction Table .....................91 
 
 
 
 
 
 
 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 20 of 93 
EudraCT: 2019-003552-36 
 
3 
GLOSSARY OF TERMS AND ABBREVIATIONS 
 
Abbreviation 
Description 
Abeta, Aβ 
amyloid beta  
AD 
Alzheimer’s disease 
ADAS-CGIC 
Alzheimer’s Disease Assessment Scale – Clinical Global Impression of 
Change 
ADAS-Cog  
Alzheimer’s Disease Assessment Scale–cognitive subscale 
ADAS-Cog-14  
Alzheimer’s Disease Assessment Scale–cognitive subscale 
ADCS 
Alzheimer's Disease Cooperative Study 
AE 
adverse event 
A-IADL-Q 
Amsterdam – Instrumental Activities of Daily Living questionnaire 
AKI 
acute kidney injury 
ALT 
alanine aminotransferase 
AEC-c 
Amplitude Envelope Correlation 
APOE 
gene that codes for apolipoprotein E 
AST 
aspartate aminotransferase 
AUC 
area under the concentration-time curve 
β-HCG 
beta human chorionic gonadotropin 
BACE 
beta secretase cleaving enzyme 
BP 
systolic and diastolic blood pressure 
BUN 
blood urea nitrogen 
C 
Celsius 
CFR 
Code of Federal Regulations 
CFT 
Category Fluency Test 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 21 of 93 
EudraCT: 2019-003552-36 
 
CKD-EPI 
Chronic Kidney Disease -Epidemiology Collaboration 
Cmax 
maximum concentration 
COWAT 
Controlled Word Association Test 
CSF 
cerebrospinal fluid 
C-SSRS 
Columbia Suicide Severity Rating Scale 
CYP 
cytochrome P450 
CYP3A4 
cytochrome P450 3A4 
dL 
deciliter 
DSMB 
data safety monitoring board 
ECG 
electrocardiogram 
EEG 
electroencephalography 
EOS 
end-of-study [visit] 
F 
Fahrenheit 
FBR 
future biomedical research  
GCP 
good clinical practice 
GDS 
Geriatric Depression Scale 
GFR 
glomerular filtration rate 
h 
hour(s) 
Hba1c 
hemoglobin A1c 
HBsAg 
hepatitis B surface antigen 
HCV 
hepatitis C virus 
HDL 
high-density lipoprotein 
hERG 
human ether-à-go-go related gene 
Hgb 
hemoglobin 
HIV 
human immunodeficiency virus 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 22 of 93 
EudraCT: 2019-003552-36 
 
HPMC 
hydroxypropyl methylcellulose 
Hz 
Hertz 
IC50 
half maximal inhibitory concentration 
ICF 
informed consent form 
ICH 
International Conference on Harmonization 
INR 
international normalized ratio 
IUD 
intrauterine device 
IRB 
Institutional Review Board 
KIM-1 
kidney injury molecule -1 
LDH 
lactate dehydrogenase 
LDL 
low-density lipoprotein 
LP 
lumbar puncture 
MeSH 
Medical Subject Headings 
MAD 
multiple ascending dose 
MCHC 
mean corpuscular hemoglobin concentration  
MCI 
mild cognitive impairment 
MCV 
mean corpuscular volume 
µg 
microgram 
mL 
milliliter 
mmol 
millimolar 
MMSE 
Mini-Mental State Exam 
MRI 
magnetic resonance imaging 
MTD 
maximum tolerated dose 
NIH 
National Institutes of Health 
NIA 
National Institute on Aging 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 23 of 93 
EudraCT: 2019-003552-36 
 
NSAIDs 
nonsteroidal anti-inflammatory drugs 
NTB 
neuropsychological test battery 
PD 
pharmacodynamics 
P-gp 
P-glycoprotein 
PGRMC1 
Progesterone receptor membrane compound 1 
PK 
pharmacokinetic(s) 
QD 
once daily 
SAE 
serious adverse event 
t1/2 
terminal half-life 
TSH 
thyroid stimulating hormone 
TMT A & B 
Trail Making Test A and B 
ULN 
upper limit of normal 
VMDS 
Wechsler Memory Digit Span 
 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 24 of 93 
EudraCT: 2019-003552-36 
 
4 
INTRODUCTION 
4.1 
Background 
Synaptic dysfunction and loss caused by age-dependent accumulation of synaptotoxic beta-
amyloid (Abeta) 1-42 oligomers is proposed to underlie cognitive decline in Alzheimer’s disease 
(AD). Accumulation of Abeta protein leads to self-association, resulting in formation of 
oligomers. Cognition Therapeutics Inc. has demonstrated that Abeta oligomers bind saturably to 
a single high affinity site on the surface of neuronal synapses (Izzo et al 2014a, b). Once bound, 
these oligomers alter membrane trafficking rate and reduce surface expression of neuronal 
receptors critical for synaptic plasticity (Hsieh 2006, Lacor 2007). This leads to failure of 
long-term potentiation, reversible spine loss in neurons, and impaired cognitive performance 
that progresses throughout the course of AD (Shankar 2007, Zempel 2013). Cognition 
Therapeutics Inc. has identified a receptor not previously associated with AD that mediates the 
binding of Abeta oligomers to neurons, the sigma-2/PGRMC1 receptor (Izzo et al 2014a, b).  
Cognition Therapeutics has discovered a series of highly brain penetrant, novel 
sigma-2/PGRMC1 antagonist molecules, including CT1812 that both prevent and competitively 
displace oligomer binding to neuronal synapses, prevent spine loss in neurons and prevent and 
treat oligomer-induced deficits in membrane trafficking in vitro. These antagonists displace 
endogenous human AD oligomers from brain tissue sections in a dose-dependent manner. 
Chronic administration of sigma-2/PGRMC1 antagonists at doses that reach brain 
concentrations corresponding to greater than 80% estimated receptor occupancy at the sigma-
2/PGRMC1 receptor restore cognitive function in aged transgenic hAPP Swe/Ldn mice models 
of AD. These molecules work by allosteric antagonism of the sigma-2/PGRMC1 receptor protein 
or a protein closely associated with it to modulate oligomer binding site affinity, representing a 
novel previously unrecognized mechanism of action for disease-modifying Alzheimer’s 
therapeutics. 
CT1812 is a highly brain penetrant novel sigma-2/PGRMC1 antagonist molecule that prevents 
and displaces binding of Abeta42 oligomers to receptors on brain cells. In vitro, in-cultured rat 
neurons, CT1812 not only antagonizes binding of Abeta42 oligomers, but also prevents Abeta 
oligomer-induced membrane trafficking changes. Chronic treatment with this first-in-class, highly 
brain-penetrant, disease-modifying oligomer receptor antagonist restores aged AD model 
transgenic mouse performance to normal in multiple cognitive tests. Sponsor hypothesizes that 
chronic treatment with CT1812 could restore neuronal plasticity compromised by Abeta 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 25 of 93 
EudraCT: 2019-003552-36 
 
oligomers, and thus improve cognitive function in patients throughout the course of AD. This 
approach is fundamentally different than that of other therapeutics in development (such as beta 
secretase cleaving enzyme [BACE] inhibitors) that focus on lowering the brain concentrations of 
beta amyloid protein. This product could provide the first clinical test of the hypothesis that 
cognitive decline in AD is related to toxic effects of Abeta oligomers on synaptic function.  
There are no currently approved products for the treatment of prodromal mild cognitive 
impairment (MCI) or established AD that function by blocking the binding and pathological 
activity of soluble Abeta oligomers. While there are some approved drugs for other indications 
that demonstrate significant affinity at sigma-2/PGRMC1 receptors, unlike CT1812, these other 
drugs have significant activity at other pharmacological targets besides the sigma-2/PGRMC-1 
receptor, which would make them undesirable therapeutic agents for this indication. None of 
these have been tested or approved for treating AD or cognitive impairment. 
Cognition Therapeutics, Inc. is developing this oral formulation of CT1812 to treat AD and mild 
cognitive impairment.  
Various techniques can be used to study brain activity and functional connectivity, but 
electroencephalography (EEG) is the only method that is available in almost every hospital. 
EEG is a non-invasive, cheap and reliable technique, making it a suitable tool for large 
interventional studies. Neuronal dysfunction caused by cerebral pathology, for example the 
deposition of toxic β-amyloid oligomers in AD, can be detected by EEG in various ways.  
For this purpose, no specific task EEG data is required. Several minutes of routinely recorded 
artifact-free, resting-state, eyes-closed EEG data is sufficient for all analyses.  
Measures expressing local brain activity are used often in the diagnostic evaluation of patients 
in clinical care. In patients with AD, the EEG shows distinct changes reflecting abnormalities of 
brain activity (Jeong 2004, Gouw et al 2017, de Waal et al 2012). In the earliest phase of AD, 
the EEG can be normal. With progression of the disease, there is a gradual, diffuse slowing of 
brain activity, reflected by changes of spectral power in conventional frequency bands. First, 
slow (theta; 4 - 8 Hz) activity increases and fast (beta, 13 - 30 Hz) activity decreases, followed 
by slowing and diminished reactivity of mid-range (alpha, 8 - 13 Hz) activity. In later stages, 
alpha activity decreases and finally very slow (delta, 0.5 - 4 Hz) power increases. In amyloid-
positive patients who have no objective cognitive disturbances, global theta power has also 
been shown to be a predictive marker of future cognitive decline (Gouw et al 2017). 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 26 of 93 
EudraCT: 2019-003552-36 
 
Since global theta activity (and in particular ‘relative theta power’) is the most powerful early-
phase diagnostic EEG marker in AD patients, it will be included in this study as primary efficacy 
outcome measure. Because of their expected additional value in early AD, several measures 
reflecting changes in brain activity will be added for exploratory purposes: relative power in 
alpha and beta bands, global peak frequency, and theta/alpha ratio. 
In addition to regional brain activity, communication between brain regions (“functional 
connectivity”) can be derived from task-free EEG. For the investigation of synaptic function, 
functional connectivity markers are especially relevant. Recent clinical studies have shown 
promising results when using specific EEG connectivity measures for treatment monitoring. 
A promising marker of functional connectivity is the so-called corrected Amplitude Envelope 
Correlation (AEC-c); it will be included as exploratory secondary endpoint (Hipp et al 2012, 
Colclough et al 2016). Built upon functional connectivity, more advanced graph theoretical 
network analysis can be performed to gain insight in changes in functional network integrity (i.e., 
topology, efficacy, robustness) during the AD disease process, but also during treatment 
periods. These can provide more insight into disease mechanisms. We will include a battery of 
state-of-the-art measures to characterize and compare overall functional brain network topology 
(minimum spanning tree analysis with measures diameter, tree hierarchy, leaf fraction, 
betweenness centrality and eccentricity), global efficiency (small world topology analysis with 
measures characteristic path length and clustering coefficient), sub-community detection 
(modularity analysis with measures Modularity index, number of modules, participation 
coefficient, within-module degree) (Rubinov & Sporns 2010, Stam et al 2014). 
 
4.2 
Nonclinical Experience 
4.2.1 Nonclinical Pharmacology Studies 
CT1812 is a lipophilic isoindoline formulated as a fumarate salt and is the result of a structure-
based medicinal chemistry optimization program comprised of more than 300 analogs. 
CT1812’s properties are fully described along with all preclinical studies in the Investigator 
Brochure. CT1812 has a high affinity at the target receptor sigma-2/PGRMC1 (S2), and is 
> 100-fold selective for this receptor over other receptors and ion channels. Dose-limiting 
toxicities at higher doses in both species appear to be hypercalcemia and renal tubular damage, 
both of which are non-invasively monitored via measurement of serum calcium and urinary 
markers of renal tubular injury such as kidney injury molecule 1 (KIM-1).  

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 27 of 93 
EudraCT: 2019-003552-36 
 
In vitro pharmacodynamics (PD) studies confirmed CT1812 target binding specificity, affinity 
and engagement, including the prevention and reversal of Aβ oligomer binding and the 
prevention of Aβ oligomer-induced synapse loss. 
In vivo PD studies confirmed the desired consequences of target engagement, including 
cognitive improvements in an aged transgenic mouse model of AD following oral administration 
of an apparently tolerated dose of CT1812 daily for 9 weeks. Additional in vivo PD studies, 
using an Aβ oligomer detecting microelectrode in an aged transgenic mouse model of AD, 
demonstrated that administration of CT1812 caused an acute increase in soluble Aβ oligomers 
in the interstitial fluid of the hippocampus and a sustained increased in soluble Aβ oligomers in 
the CSF of the lateral ventricle of the brain. These increases in soluble Aβ oligomers occurred 
without a change in the amount of soluble Aβ 1-40, indicating that displacement of Aβ oligomers 
occurred following treatment with CT1812. 
4.2.2 Nonclinical Pharmacokinetic Studies 
Absorption of CT1812 following oral gavage administration to mice, rats and dogs appears to be 
very rapid, with brain concentrations exceeding those concurrently measured in plasma. The 
drug is highly protein-bound in plasma from rat, mouse, dog, and human, but only weakly bound 
to blood cells. Systemic exposures to CT1812 following oral administration to rats and dogs 
were greater than dose-proportional at high, toxicologically relevant dosages. Extensive first-
pass metabolism appears to be via oxidation and/or direct glucuronidation. 
Studies with human recombinant cytochrome P450 (CYP) isoforms show rapid metabolism (t1/2 
of 6.8 min) by CYP3A4, and slower metabolism (t1/2 of 57 and 81 minutes) by CYP2D6 and 
CYP2C19. A direct glucuronide conjugate was also observed in vitro in human hepatocyte 
incubations, consistent with that observed in vivo in rats and dogs.  
CT1812 was not an inhibitor of CYP1A2, CYP2B6, or CYP2C8, with less than 50% inhibition of 
activity observed at the highest concentration evaluated (10 μM). CT1812 was a weak inhibitor 
of CYP2C9, CYP2C19, CYP2D6, and CYP3A4, with IC50 values ranging from 4.4 to 38 μM. 
However, when evaluated in the context of systemic exposure data in humans, the drug‐drug 
interaction liability from these effects was considered to be minimal. CT1812 was found to be an 
inducer of CYP3A4 (≥ 0.3 μM), suggesting a potentially clinically significant risk of drug-drug 
interactions with this isoform, but induction of CYP2B6 and CYP1A2 appear less likely. CT1812 
does appear to be a substrate for p‐glycoprotein (P‐gp) and inhibits P‐gp with an IC50 of 10 μM. 
This is considered to be potentially clinically significant, primarily due to the possibility of 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 28 of 93 
EudraCT: 2019-003552-36 
 
interactions in the gastrointestinal (GI) tract. In vitro inhibition of the OATP1B1 transporter (IC50 
of 11.5 µM) by CT1812 does not appear to be clinically relevant, when evaluated in the context 
of systemic exposure data in humans. As assessed per the FDA 2012 draft guidance for DDI 
evaluations, clinically relevant DDI are suggested via CT1812 effects on CYP3A4 and P-gp. 
4.2.3 Nonclinical Safety Studies 
Two hERG (human Ether-à-go-go Related Gene) assays were performed to assess effects of 
CT1812 on the rapidly activating delayed rectifier potassium channels (IKr) using channels 
stably transfected and over-expressed in Chinese Hamster Ovary cells. Using whole-cell patch 
clamp electrophysiology, CT1812 was tested in both studies in duplicate at concentrations of 1, 
3, 10, and 30 M. Mean IC50 values of 26 M and 0.6 M were determined in the first and 
second assay, respectively. Reasons for the differing results are unknown. However, no ECG 
effects were noted in the telemeterized dog cardiovascular safety study or in the multiple-dose 
dog pivotal toxicology study when tested up to high-dose mean Cmax values of approximately 
4 µM. 
Safety pharmacology studies with rats revealed no apparent effects on central nervous system 
or pulmonary parameters, following single oral dosages that exceeded the maximum tolerated 
dose in this species. 
General toxicology studies with rats and dogs following oral dosing of CT1812 revealed dose-
limiting toxicity that manifested as degenerative changes in the proximal tubules of kidney, 
hypercalcemia, and vascular mineralization and/or degeneration involving multiple tissues and 
organs in each species. Tolerable and intolerable dosages and exposures, characterized with 
each species, informed the selection of dosages for this study. 
Additionally, toxicology studies revealed several test article-related clinical laboratory changes, 
including elevated serum creatinine and/or BUN that correlated with mild weight loss, elevated 
serum calcium and reduced urinary specific gravity. The exact mechanism for these changes 
cannot be determined from those studies. Serum and urine tests will be performed in this study 
to evaluate the effect of study drug administration on renal function (including serum creatinine, 
serum calcium, and urine calcium).  
Genetic toxicology studies revealed no positive responses in bacterial and mammalian in vitro 
assays, or in an in vivo mouse bone marrow micronucleus assay when tested up to maximally 
feasible dosages. 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 29 of 93 
EudraCT: 2019-003552-36 
 
4.3 
Clinical Experience 
CT1812 has been administered safely with good tolerability in more than 60 healthy volunteers 
in a placebo-controlled Phase 1a study (COG0101). Six single (10-1120 mg) and 3 multiple 
dose cohorts (QD, 14 days, 280-840 mg) were observed under close in-patient stay (N = 6 to 8 
treated, 2 placebo per cohort). Plasma concentrations of drug were shown to be approximately 
dose proportional across 2 orders of magnitude [0.13-14.93 mg (free base equivalent)/kg], and 
accumulation was minimal. Peak concentrations of CT1812 were reached within 1 to 2 hours 
and the plasma half-life was shown to be approximately 12 hours. Adverse events (AEs) were 
mostly mild to moderate in severity and principally included headache, nausea, vomiting, 
diarrhea, constipation, abdominal pain, dyspepsia, upper respiratory tract infection, 
lightheadedness, syncope, myalgia, dizziness, rash and pain at the lumbar puncture (LP) site in 
those participants who had LPs. There was only one AE of severe intensity (a serious adverse 
event [SAE] of upper respiratory tract infection) occurring in one participant in the 840 mg dose 
of the multiple ascending dose (MAD) study, believed to be unrelated to study drug based on a 
similar pattern of URTIs in participants receiving drugs other than CT1812 in the study unit 
during the same time period. One participant in the multiple dose cohort study developed a rash 
while on study drug. This participant showed improvement after discontinuing CT1812.  
No evidence of renal toxicity has been observed to date based on routine measures of renal 
function (serum creatinine, BUN). 
Four participants in the MAD study showed an increase in liver function tests below 3X the 
upper limit of normal (including one participant on placebo). Subsequent studies will closely 
monitor liver enzyme parameters to determine if these were sporadic findings or possibly drug-
related. 
A fed cohort (280 mg) single dose was compared to the fasting cohort of 280 mg and no 
significant food effect was observed. A multiple dose cohort of elderly (≥65 years old) healthy 
volunteers was dosed at 560 mg x 14 days, and their exposures were similar to the 840 mg 
younger healthy volunteer participants. 
In COG0103, 15 healthy volunteers evaluated potential effects of CT1812 on the disposition of 
sensitive substrates of selected CYP isoenzymes CYP2C19 (omeprazole), CYP2C9 
(tolbutamide), CYP2D6 (dextromethorphan), and CYP3A4/5 (midazolam). Participants were 
administered the probe drugs on Day -2; and followed by pharmacokinetic (PK) evaluations. On 
Days 1 through 6, each participant took CT1812 560 mg. The CT1812 dose on Day 6 was taken 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 30 of 93 
EudraCT: 2019-003552-36 
 
concomitantly with the probe drug cocktail, and PK evaluation was conducted. No significant 
interaction was observed for isoenzymes 2C19 and 2C9. A weak drug interaction was observed 
between steady-state CT1812 and midazolam 4 mg (CYP3A4). Midazolam AUClast and the 
AUClast ratio (parent to metabolite) decreased by 24% and 28%, respectively, when midazolam 
4 mg was taken with steady state CT1812 than when midazolam was taken alone. A weak drug 
interaction was observed between steady-state CT1812 and dextromethorphan 50 mg 
(CYP2D6), as indicated by a 1.75-fold and 2-fold increase in dextromethorphan AUClast and 
Cmax, respectively, following the combination treatment relative to dextromethorphan alone; 
however, the dextromethorphan/dextrorphan AUClast ratio was similar between treatments. 
Based on the small magnitude of the interactions observed in this study for the isoenzymes 
CYP2D6 and CYP3A4, clinically meaningful implications are unlikely.  
A Phase 1 study (COG0102) has completed enrollment in Australia, evaluating the safety and 
PK of 3 dose levels of CT1812 (90 mg, 280 mg, 560 mg) or matching placebo, administered 
once daily for 28 days in participants with mild to moderate Alzheimer’s disease. This study 
enrolled 19 participants in a 1:1:1:1 ratio. In general, all doses were relatively well tolerated. 
There were no deaths or SAEs. All AEs were considered mild or moderate. While there was an 
increased frequency observed in total AEs with increasing dose, the small number of treated 
participants does not permit definitive conclusions regarding the incidence of AEs by dose in a 
larger study population. Specific AEs that were noted to occur with greater frequency at the 560 
mg dose included transient lymphocytopenia, nausea, vomiting, headache, fatigue, and 
depression. These AEs resolved in most instances while treatment was ongoing; one participant 
at the 560 mg dose experienced an ALT increase of 4.7 X ULN that resolved to normal levels 
after discontinuation of study drug. Cognitive outcomes were similar across the treatment 
groups. Plasma CT1812 concentration increased approximately dose proportionally, with a dose 
dependent increase in CSF concentration. CSF concentrations at all tested doses were > 80% 
of estimated brain PGRMC-1 receptor occupancy, which was the threshold associated with 
efficacy in preclinical studies.  
EEG measures the synchronous extracellular ion flow due to excitatory and inhibitory 
postsynaptic potentials in groups of synchronized cortical neurons. The effect of neuroactive 
agents that change synaptic function and/or these postsynaptic potentials can be measured by 
changes in EEG oscillatory activity. Local activity changes are commonly described using 
spectral power measures. In patients with AD, the EEG shows distinct changes in spectral 
power indicating diffuse slowing of brain activity with disease progression (Jeong 2004, Gouw et 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 31 of 93 
EudraCT: 2019-003552-36 
 
al 2017). Treatment studies using task free EEG spectral measures show specific reversal of 
this oscillatory slowing to approved AD therapeutics (Gianotti et al 2008, Scheltens et al 2018). 
A short-term treatment study with rivastigmine resulted in decreased delta and theta absolute 
power (Adler and Brassen, 2001) whereas donepezil showed a decrease in global theta power 
(Brassen and Adler, 2003). A short-term decrease in theta power also predicted response to 
rivastigmine treatment after 6 months (Adler et al., 2004). Decreases in theta power were also 
observed with memantine (Baliboni 2013).  
4.4 
Rationale for Study 
CT1812 was shown to be safe and well tolerated in a study of healthy volunteers and in 
Phase 1 studies of participants with mild to moderate Alzheimer’s disease. This Phase 2 study 
is designed to identify measures of target engagement that reflect the rapid mechanism of action 
of CT1812 to restore synapse number to normal. We expect that the ability of CT1812 to rapidly 
restore synapse number to normal will result in a decrease in EEG theta power in AD patients in 
response to short-term treatment with CT1812.  
4.4.1 
Rationale for Selected Dose 
Based on brain receptor occupancy studies in animals, the daily dose of 300 mg/day is 
projected to exceed 95% receptor occupancy.  In a Phase 1 multiple dose, 2-week study, doses 
exceeding 300 mg/day were well-tolerated in both younger (aged ≤ 64 years) and older (aged ≥ 
65 years) participants. In the phase 1 AD study, tolerability was also acceptable with no severe 
or serious AEs observed at doses exceeding 300 mg/day. 
5 
STUDY OBJECTIVES 
5.1 
Primary 
 
To evaluate the safety, tolerability, and PK of CT1812 following repeated dosing of CT1812 
for 29 days. 
 
To evaluate the efficacy of CT1812 in restoring synaptic function in participants with mild to 
moderate Alzheimer’s disease through quantitative EEG, as reflected by relative theta 
power.  

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 32 of 93 
EudraCT: 2019-003552-36 
 
5.2 
Exploratory 
 
Measure changes in exploratory CSF and plasma biomarkers including synaptic damage 
biomarkers such as neurogranin as well as disease progression biomarkers (such as Aβ40 
and 42) measured at baseline and through the end of each treatment period. 
 
To evaluate changes in cognitive and global functioning, as measured by the Alzheimer’s 
Disease Assessment Scale–cognitive subscale-14 (ADAS-Cog-14); Alzheimer's Disease 
Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC); Amsterdam 
Instrumental Activities of Daily Living Questionnaire (A-IADL-Q); and, a neuropsychological 
test battery (NTB) that includes Category Fluency Test (CFT), Controlled Word Association 
Test (COWAT), Trail Making Test (TMT) Parts A & B, and Wechsler Memory Digit Span 
(VMDS). 
 
Evaluate additional quantitative EEG measures that have shown promise as 
diagnostic/treatment marker: relative alpha (8-13 Hz) and beta (13-30 Hz) power, 
theta/alpha power ratio, spectral peak frequency, and functional connectivity measures 
corrected Amplitude Envelope Correlation (AEC-c). 
6 
STUDY TYPE AND DESIGN 
6.1 
Study Type 
This is a single-site, randomized, double-blind, placebo-controlled, 29-day, 2-period, crossover 
Phase 2 study. 
6.2 
Endpoints 
6.2.1 Exploratory Efficacy Endpoints 
 
EEG spectral measures, specifically relative theta (4-8 Hz) power. 
 
ADAS-Cog-14 
 
ADCS-CGIC 
 
A-IADL-Q 
 
NTB, which includes: 
o CFT 
o COWAT 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 33 of 93 
EudraCT: 2019-003552-36 
 
o TMT A & B 
o VMDS 
 
CSF protein concentration (AB42 and AB40 monomers, total tau, phospho-tau, 
neurogranin, and SNAP-25). 
 
6.2.2 Safety Endpoints 
 
The incidence and severity of adverse events. 
 
The change in usage of concomitant medications. 
 
Changes in vital signs. 
 
Changes in physical examination findings. 
 
Changes in ECG findings. 
 
Changes in clinical laboratory testing (serum chemistry, hematology, urinalysis). 
 
Changes in the Columbia Suicide Severity Rating Scale (C-SSRS). 
 
6.2.3 Pharmacokinetic/Pharmacodynamic Endpoints 
 
Pharmacokinetics:  
o CT1812 CSF/plasma concentration ratio (end-of-study [EOS] only). 
o Changes in predose CT1812 plasma concentrations. 
6.3 
Study Design  
This study is a single-site, randomized, double-blind, placebo-controlled, 2-period crossover 
study in 16 mild to moderate Alzheimer’s patients (MMSE 18-26) who will receive 300 mg of 
CT1812 or placebo once daily. These patients will be organized in 2 groups of 8 patients each. 
The patients in one group will receive 29 days of treatment with CT1812 [period 1] followed by a 
14-day washout period, then 29 days treatment with placebo [period 2]. The patients in the 
second group will receive placebo for 29 days during period 1, followed by a 14-day washout 
period, then CT1812 for 29 days during period 2. Change in synaptic function and cognition will 
be assessed by quantitative EEG, A-ADL-Q, and ADAS-Cog-14, supplemented with additional 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 34 of 93 
EudraCT: 2019-003552-36 
 
cognitive tests including NTB and a clinician’s global impression at the end of Treatment 
Periods 1 and 2.  
Participants will ingest study drug each morning at home with or without food, except on study 
site days when study drug will be administered at the study site. Participants and their study 
partners will return to the study site for repeat psychometric/neurologic testing, safety 
procedures and PK and PD sample collection at the intervals described below. 
Up to 16 participants will be enrolled and will return to the study site on Days 1, 3, 8, 15, 22, and 
29. A washout period will occur between days 30 to 43 followed by additional study site visits on 
Days 44, 46, 51, 58, 65, and 72. An EOS follow-up visit will be completed on Day 84; 
approximately 12 days after the end of treatment. 
Participants will be provided with 31 days of study drug to ensure treatment is continued up to 
the last study visit days (29 +/- 2 and 72 +/=2)).  
Participants who prematurely discontinue the study for any reason will be asked to attend a final 
safety and efficacy visit.  
7 
STUDY DRUG 
7.1 
Supply and Storage 
CT1812 will be provided to the site pharmacy as a hydroxypropyl methylcellulose (HPMC) 
capsule containing 64 mg of CT1812 fumarate salt (equivalent to 150 mg of the CT1812 free 
base, respectively). Study drug will be provided in amber-colored, induction-sealed, screw-top 
bottles with desiccant packs.  
All study drug (unopened and opened bottles) will be stored between 2 to 8 degrees Celsius.  
Identical placebo capsules containing lactose monohydrate will also be supplied to match the 
CT1812 supplies in the same packaging and will require the same storage conditions (i.e., 
between 2 to 8 degrees Celsius). 
7.2 
Packaging and Labeling 
The label on the participant bottles will contain the following information in the English language: 
 
Protocol number: COG0202. 
 
Expiration date. 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 35 of 93 
EudraCT: 2019-003552-36 
 
 
Lot number. 
 
Contents. 
 
Weight. 
 
Storage conditions. 
 
The sentence, “For Clinical Trial Use Only.” 
 
Name of the Investigator. 
 
Name, address and telephone number of the Sponsor. 
7.3 
Administration 
CT1812 or matching placebo will be administered orally as a single daily dose for 29 days. Each 
dose CT1812 or matching placebo will consist of 2 capsules. All participants will ingest the first 
dose at the study site and be observed for 2 hours. Capsules will be swallowed with 
approximately 240 mL of water with or without food. Daily outpatient dosing should occur in the 
morning (i.e., prior to 12 pm/noon). To ensure appropriate specimen collection times relative to 
dosing on study site days, participants will be asked to bring their study drug to study site visits 
and to take their study drug at the study site upon the instruction of the site staff. On “Drug 
dispensing” study site visits drug accountability will be completed for the bottle returned by the 
participant and the “Dose administration at study site” will be taken for that visit from the newly 
assigned bottle. 
7.3.1 Safety Stopping Rules 
For all participants: 
The occurrence of any one of the following events will result in suspension of administration of 
study drug in all participants until safety information can be further reviewed by the Sponsor and 
Medical Monitor. 
 
Two occurrences of the same or similar serious adverse event (SAE) assessed as 
probably or possibly related to dosing with investigational product  
 
Two or more different participants with the same or similar severe AE assessed as 
probably or possibly related to dosing with the investigational product 
 
Four or more participants with the same or similar moderate AE that is possibly or 
probably related to dosing with investigational product 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 36 of 93 
EudraCT: 2019-003552-36 
 
Under these circumstances, the Sponsor and Medical Monitor will review the available safety 
data and, in consultation with the site’s Principal Investigator, recommend whether dosing 
should continue, or if study drug administration should be terminated, or if additional monitoring 
procedures or safety precautions need to be employed.  
If a stopping rule is achieved, selective unblinding of the participants involved may be performed 
by the Sponsor to determine if the SAEs/AEs are isolated to a single dose group or if they 
occurred in placebo participants.  
The study or a dose group may also be terminated if the Medical Monitor, Study Director, and 
Sponsor, in consultation with the site’s Principal Investigator, determine that any adverse 
event(s) are occurring that are intolerable or pose a medically unacceptable safety risk. 
For individual participants:  
Participants who develop a severe adverse event or laboratory abnormality will not receive any 
additional doses and will be monitored until resolution of the AE or the return of laboratory 
abnormality to the acceptable screening value(s). Study drug may be re-initiated after 
consultation with Medical Monitor and Sponsor. Any participant with: 
 
Elevated ALT or AST greater than 5 X ULN should have dosing with study drug stopped 
and have laboratory tests repeated every 3 to 4 days until levels return to less than or 
equal to 1.5 X ULN. If the Medical Monitor and Investigator are in agreement, study drug 
may be continued while a confirmatory ALT/AST is obtained within 3 days. If the 
confirmatory ALT/AST tests are below 5 X ULN, study drug may be continued. The 
frequency of the laboratory tests may be modified after discussion with the Medical 
Monitor if the liver enzymes are in a decreasing trend.  
 
Elevated ALT or AST greater than 3 X ULN in combination with total bilirubin > 2 X ULN 
or INR > 1.5 X ULN OR an ALT or AST > 3 X ULN with the appearance of fatigue, 
nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or 
eosinophilia (> 5%) should have dosing with study drug stopped and have laboratory 
testing repeated every 3 to 4 days. If the Medical Monitor and Investigator are in 
agreement, study drug may be continued while a confirmatory laboratory testing is 
obtained within 3 days. If these criteria are no longer met, study drug can be continued 
at the discretion of the Medical Monitor and Investigator. The frequency of the laboratory 
tests may be modified after discussion with the Medical Monitor if the laboratory tests 
are trending towards normal.  

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 37 of 93 
EudraCT: 2019-003552-36 
 
 
An increase in serum creatinine by 0.3 mg/dL (24.4 micromol/L) or 150% of baseline, 
which is without clinical explanation of another etiology, will result in repeated 
serum chemistry testing within 3 to 7 days. If the serum creatinine elevation is confirmed 
on repeated testing the study drug will be discontinued. If the serum creatinine elevation 
resolves upon subsequent testing after study drug is discontinued the study drug may be 
restarted with serum creatinine monitoring at the discretion of the Medical Monitor and 
Investigator. 
 
An increase in serum calcium to ≥10.5 mg/dl (2.63 mmol/L), which is without clinical 
explanation of another etiology, will result in repeated serum chemistry testing within 3 to 
7 days. If the serum calcium elevation is confirmed on repeated testing the study drug 
will be discontinued. If the serum calcium elevation resolves upon subsequent testing 
after study drug is discontinued the study drug may be restarted with serum calcium 
monitoring at the discretion of the Medical Monitor and Investigator. 
 
Note: Fractional excretion of calcium will be monitored in each participant and 
interpreted in conjunction with serum creatinine and serum calcium. Given the ability of 
fractional excretion to fluctuate, no upper limit for discontinuing study drug based on 
fractional excretion of calcium has been set but it may be used as a stopping rule if 
persistent unexplained increases in fractional excretion of calcium are observed. 
7.4 
Drug Accountability 
Participants will return all study bottles and unused study drug at each study site visit for drug 
accountability to be performed. The Investigator or their appointed designee is responsible for 
ensuring that deliveries of study drug are correctly dispensed and recorded, that the product is 
handled and stored safely and properly, and that it is only being given to participants in 
accordance with this protocol.  
Sites will keep a current log of drug accountability recording:  
 
What drug supply was received from the Sponsor. 
 
What drug supply was dispensed to each participant. 
 
What drug supply is current in inventory. 
 
What drug supply was destroyed or returned to the Sponsor for destruction. 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 38 of 93 
EudraCT: 2019-003552-36 
 
Note: Drug accountability is the responsibility of the Investigator; a written account will be 
required for all discrepancies. 
The Sponsor’s designated Monitor must verify all accountability records during periodic 
monitoring visits. Unused and used study drug must be stored on site until such accountability 
has taken place and authorization is received from the Sponsor or Sponsor’s designee that the 
study drug may be returned or destroyed. 
7.5 
Overdose/Toxicity Management 
No specific pharmacologic antagonist or antidote exists for CT1812. Therefore, overdose or 
clinical toxicity should be managed with supportive care and pharmacologic treatments directed 
at specific symptoms (i.e., benzodiazepines for agitation or antipyretics for fever). 
7.6 
Blinding, Randomization, and Matching Participants 
This is a double-blind, placebo-controlled study. Study treatment will consist of capsules of 
CT1812 and matching placebo. The placebo capsule will be identical in appearance to the 
active CT1812 capsule. 
The non-blinded statistician assigned to the study will generate a list with the appropriate 
number of 4-digit individual study IDs randomly for each arm, randomly assigned to either active 
study drug or placebo. 
Should any participant withdraw from the study prior to study completion, the participant may be 
replaced, at the discretion of the Sponsor. The replacement participant will be given the same 
treatment assignment (by the unblinded statistician) as the withdrawn participant. 
8 
INVESTIGATORS, SITES AND DURATION 
8.1 
Investigator and Study Site 
This single-center study will be conducted at the VU University Medical Center (VUmc) in 
Amsterdam, The Netherlands, under the Direction of Everard Vijverberg, MD, Ph.D. 
8.2 
Duration of Study 
Screening procedures will occur on Days -42 to -1. Eligible participants will return to the study 
site at the Baseline/Day 1 visit to be randomly assigned to either active study drug or placebo. 
The first treatment period (29 days) will be followed by a 14-day washout. Immediately after the 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 39 of 93 
EudraCT: 2019-003552-36 
 
washout, there will be a second treatment period for 29 days, followed by a 12-day safety 
follow-up period. The total duration of participant participation in the study, including the 
screening period, is up to 126 days. 
8.3 
Termination of Study 
This study may be terminated at the discretion of the Sponsor.  
9 
STUDY POPULATION  
9.1 
Number of Participants 
Up to 16 participants will be randomized.  
9.2 
Inclusion Criteria 
Participants may be included in the study only if they meet all of the following criteria: 
1) Women of non-childbearing potential and men, aged 50 to 85 years, inclusive, with a 
diagnosis of mild to moderate Alzheimer’s disease according to the 2018 NIA-AA criteria 
and at least a 6-month history of decline in cognitive function documented in the medical 
record. 
i) 
Non-childbearing potential for women is defined as postmenopausal (last menses 
greater than 24 months) or undergone a documented bilateral tubal ligation or 
hysterectomy. If last menses less than 24 months, a serum follicle stimulating 
hormone (FSH) value confirming post-menopausal status may be used. 
ii) Male participants who are sexually active with a woman of child-bearing potential 
must agree to use condoms during the study and for 3 months after last dose. 
Female partners should also consider using an acceptable means of birth control, 
though it is not mandatory. Acceptable forms of birth control include abstinence, birth 
control pills, or any double combination of: intrauterine device (IUD), male or female 
condom, diaphragm, sponge, and cervical cap. 
2) CSF meets CSF abeta 1‐42 (abeta) and p-tau -181 criteria as defined below.  
 
CSF abeta 1‐42 < 1000pg/ml (Elecsys assay) AND 
CSF p‐tau 181 > 19 pg/ml (Elecsys Assay) 
 
OR:   

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 40 of 93 
EudraCT: 2019-003552-36 
 
CSF abeta 1‐42 < 1000pg/ml (Elecsys assay) AND 
p‐tau ‐181 / abeta 1‐42 ratio > 0.020 
 
OR: 
CSF p‐tau 181 > 19 pg/ml (Elcsys Assay) AND 
p‐tau ‐181 / abeta 1‐42 ratio > 0.020 
 
Historical CSF results will be considered provided the results are consistent with the CSF 
thresholds required for inclusion and following discussion with the medical monitor; 
however, an LP is still required as part of screening procedures. 
3) Neuroimaging (MRI) consistent with the clinical diagnosis of Alzheimer’s disease and 
without findings of significant exclusionary abnormalities (see Section 9.3 exclusion criteria 
no. 4). An historical MRI, up to 1 year prior to screening, may be used as long as there have 
been no interval clinical neurologic events that may suggest a change in the MRI scan. 
4) MMSE 18-26 inclusive. 
5) Geriatric Depression Scale (GDS) ≤ 6 with no active depression (see Section 9.3 exclusion 
criteria no. 6). 
6) Formal education of 8 or more years. 
7) Participants must have a caregiver/study partner who in the opinion of the site’s Principal 
Investigator, has contact with the study participant for a sufficient number of hours per week 
to provide informative responses on the protocol assessments, oversee the administration of 
study drug, and is willing and able to participate in all study site visits and some study 
assessments. The caregiver/ study partner must provide written informed consent to 
participate in the study.  
8) Participants living at home or in the community (assisted living acceptable). 
9) Participants must have no known history of difficulty swallowing capsules. 
10) Stable pharmacological treatment of any other chronic conditions for at least 30 days prior to 
screening. 
11) Must consent to apolipoprotein E (APOE) genotyping. 
12) Participants shall be generally healthy with mobility (ambulatory or ambulatory-aided, i.e., 
walker or cane), vision and hearing (hearing aid permissible) sufficient for compliance with 
testing procedures. 
13) Must be able to complete all screening evaluations. 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 41 of 93 
EudraCT: 2019-003552-36 
 
9.3 
Exclusion Criteria 
Participants will be excluded from the study if any of the following conditions apply: 
1) Hospitalization (except for planned procedures) or change of chronic concomitant 
medication within 1 month prior to screening. 
2) Participants living in a continuous care nursing facility. 
3) Contraindications to the MRI examination for any reason. 
4) Screening MRI (or historical MRI, if applicable) of the brain indicative of significant 
abnormality, including, but not limited to, prior hemorrhage or infarct > 1 cm3, > 3 lacunar 
infarcts, cerebral contusion, encephalomalacia, aneurysm, vascular malformation, subdural 
hematoma, hydrocephalus, space-occupying lesion (e.g., abscess or brain tumor such as 
meningioma).  
5) Clinical or laboratory findings consistent with: 
a) Other primary degenerative dementia, (dementia with Lewy bodies, fronto-temporal 
dementia, Huntington’s disease, Creutzfeldt-Jakob Disease, Down syndrome, etc.). 
b) Other neurodegenerative condition (Parkinson’s disease, amyotrophic lateral sclerosis, 
etc.). 
c) Seizure disorder. 
d) Other infectious, metabolic or systemic diseases affecting the central nervous system 
(syphilis, present hypothyroidism, present vitamin B12 or folate deficiency, other 
laboratory values etc.). 
6) A current DSM-V diagnosis of active major depression, schizophrenia or bipolar disorder. 
Participants with depressive symptoms successfully managed by a stable dose of an 
antidepressant are allowed entry. 
7) Clinically significant, advanced or unstable disease that may interfere with outcome 
evaluations, such as: 
a) Chronic liver disease, liver function test abnormalities or other signs of hepatic 
insufficiency (ALT, AST, alkaline phosphatase > 1.5 ULN, lactate dehydrogenase (LDH) 
> 1.5 x ULN). 
b) Respiratory insufficiency. 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 42 of 93 
EudraCT: 2019-003552-36 
 
c) Renal insufficiency eGFR < 50 mL/min based on the CKD-EPI formula, 
https://www.mdcalc.com/ckd-epi-equations-glomerular-filtration-rate-gfr 
d) Heart disease (myocardial infarction, unstable angina, heart failure, cardiomyopathy 
within 6 months before screening). 
e) Bradycardia (< 50/min.) or tachycardia (> 100/min.). 
f) Poorly managed hypertension (systolic > 160 mm Hg and/or diastolic > 95 mm Hg) or 
hypotension (systolic < 90 mm Hg and/or diastolic < 60 mm Hg). 
g) Uncontrolled diabetes in known diabetics, as defined by hemoglobin A1c (HbA1c) > 7.5. 
8) History of cancer within 3 years of screening with the exception of fully excised non-
melanoma skin cancers or non-metastatic prostate cancer that has been stable for at least 
6 months. 
9) Seropositive for human immunodeficiency virus (HIV). 
10) History of acute/chronic hepatitis B or C and/or carriers of hepatitis B (seropositive for 
hepatitis B surface antigen [HbsAg] or anti-hepatitis C [HCV] antibody). 
11) Clinically significant abnormalities in screening laboratory tests, including:  
a) Hematocrit less than 35% for males and less than 32% for females, absolute neutrophil 
cell count of <1500/uL (with the exception of a documented history of a chronic benign 
neutropenia), or platelet cell count of < 120,000/uL; international normalized ratio 
(INR) > 1.4 or other coagulopathy, confirmed by repeat assessment of: 
i) 
Hematocrit. 
ii) Neutrophil count. 
iii) Platelet count. 
12) Disability that may prevent the participant from completing all study requirements (e.g., 
blindness, deafness, severe language difficulty, etc.). 
13) Within 4 weeks of screening visit or during the study, concurrent treatment with antipsychotic 
agents, antiepileptics, centrally active anti-hypertensive drugs (e.g., clonidine, l-methyl dopa, 
guanidine, guanfacine, etc.), sedatives, opioids, mood stabilizers (e.g., valproate, lithium); or 
benzodiazepines, with the following exception:  

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 43 of 93 
EudraCT: 2019-003552-36 
 
a) Low dose lorazepam may be used for sedation prior to MRI scan for those participants 
requiring sedation. At the discretion of the Investigator, 0.5 to 1 mg may be given orally 
prior to scan with a single repeat dose given if the first dose is ineffective. No more than 
a total of 2 mg lorazepam may be used for the MRI scan.  
14) Any disorder that could interfere with the absorption, distribution, metabolism or excretion of 
drugs (e.g., small bowel disease, Crohn’s disease, celiac disease, or liver disease). 
15) Nootropic drugs except stable AD meds (acetylcholinesterase inhibitors and memantine). 
16) Suspected or known drug or alcohol abuse, i.e., more than approximately 60 g alcohol 
(approximately 1 liter of beer or 0.5 liter of wine) per day. 
17) Suspected or known allergy to any components of the study treatments. 
18) Enrollment in another investigational study or intake of investigational drug within the 
previous 30 days or 5 half-lives of the investigational drug, whichever is longer. 
19) Intake of drugs or substances potentially involved in clinically significant induction or 
inhibition of CYP3A4 or P-gp mediated drug interactions with CT1812, within 4 weeks or 
5 half-lives of the interacting drug prior to administration of CT1812 and throughout the 
study. Grapefruit juice should be avoided in the 2 weeks prior to dosing and throughout the 
study. See Appendix A for a complete list of prohibited substances. 
20) Exposure to immunomodulators, anti Aβ vaccines, passive immunotherapies for AD (e.g., 
monoclonal antibodies) within the past 180 days and/or exposure to BACE inhibitors within 
the past 30 days 
21)  Anticipated use of nonsteroidal anti-inflammatory drugs (NSAIDs) on more than 14 days 
from Baseline/Day 1 to Day 182. Contraindication to undergoing an LP including, but not 
limited to: inability to tolerate an appropriately flexed position for the time necessary to 
perform an LP; international normalized ratio (INR) > 1.4 or other coagulopathy; platelet 
count of < 120,000/μL; infection at the desired LP site; taking anti-coagulant medication 
within 90 days of screening (low-dose aspirin is permitted); degenerative arthritis of the 
lumbar spine; suspected non-communicating hydrocephalus or intracranial mass; prior 
history of spinal mass or trauma. 
22) Any condition, which in the opinion of the Investigator or the Sponsor, makes the participant 
unsuitable for inclusion. 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 44 of 93 
EudraCT: 2019-003552-36 
 
9.4 
Withdrawal of Participants 
A participant should be withdrawn from the study if any of the following occur: 
1. 
Withdrawal of participant consent. 
2. 
Investigator determines that withdrawal from the study is in the best interest of the 
participant. 
3. 
Major protocol violation (i.e., circumstances where confounding conditions make it 
impossible to derive sound scientific or medical conclusions from the primary endpoint 
data generated on a participant).  
4. 
Any condition, injury, or disease that becomes apparent during the study and necessitates 
the termination of the participant from the study; including events detailed in Section 7.3.1 
- Safety Stopping Rules. 
5. 
Administrative reason (e.g., termination of the clinical study by a regulatory agency or the 
Sponsor). 
9.5 
Participant Withdrawal Procedures 
9.5.1 Follow-up Procedures for Participants Who Withdraw Prematurely 
The date and the reason for study drug discontinuation or participant withdrawal from the study 
must be recorded on the Case Report Form. If the participant has received one or more doses 
of clinical study material, and has not withdrawn consent, the participant shall return for the EOS 
visit. The EOS visit for early terminations will occur within 2 weeks of the last dose. 
9.6 
Procedures for Replacing Participants Who Withdraw Prematurely 
Participants who withdraw from the study prior to dosing may be replaced after consultation with 
the Sponsor. If a participant is replaced, instructions in Section 7.6 will be followed for 
randomization and assignment of a study number. 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 45 of 93 
EudraCT: 2019-003552-36 
 
10 TREATMENT PLAN AND METHODS 
10.1 Schedule of Assessments 
 
Table 1 – Schedule of Assessments 
 
Period 
Screen 
Baseline 
Treatment Period 1 
Wash 
Treatment Period 2 
F/U 
 
Visit 
1 
2 
3 
4 
5 
6 
7 
 
8 
9 
10 
11 
12 
13 
14 
 
Study day 
-42 to -1 
1 
3 
8 
(±2) 
15 
(±2) 
22 
(±2) 
29 
(±2) 
30 to 
43 
44 
(±2) 
46 
(±2) 
51 
(±2) 
58 
(±2) 
65 
(±2) 
72 
(±2) 
84 
(±2) 
1 
Informed consent 
X 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
2 
Inclusion/exclusion criteria 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
Demography & medical history 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 
Confirm AD diagnosis  
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
MMSE, GDS 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 
MRI, Imaging 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7 
Complete physical examination  
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
X 
8 
Brief physical examination 
 
 
 
X 
X 
X 
X 
 
X 
 
X 
X 
X 
X 
 
9 
Vital signs 
X 
X 
 
X 
X 
X 
X 
 
X 
 
X 
X 
X 
X 
X 
10 
ECG (12-lead) 
X 
X 
 
 
X 
 
 
 
X 
 
X 
 
 
 
X 
11 
EEG 
 
X 
 
 
 
 
X 
 
X 
 
 
 
 
X 
X 
 
Blood Draws & Lumbar Puncture 
12 
APOE status 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13 
Screening laboratories 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
14 
Chemistry, hematology, viral serology 
and lipid panel 
X 
X 
 
X 
X 
X 
X 
 
X 
 
X 
X 
X 
X 
X 
15 
Whole blood for FSH, if applicable  
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
16 
Whole blood for future biomedical 
research 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
17 
Blood and plasma for PK/PD 
sampling and exploratory biomarkers 
 
a 
 
b 
b 
b 
a 
 
a 
 
b 
b 
b 
a 
c 
18 
Lumbar puncture 
X 
 
 
 
 
 
X 
 
 
 
 
 
 
X 
 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 46 of 93 
EudraCT: 2019-003552-36 
 
 
Period 
Screen 
Baseline 
Treatment Period 1 
Wash 
Treatment Period 2 
F/U 
 
Visit 
1 
2 
3 
4 
5 
6 
7 
 
8 
9 
10 
11 
12 
13 
14 
 
Study day 
-42 to -1 
1 
3 
8 
(±2) 
15 
(±2) 
22 
(±2) 
29 
(±2) 
30 to 
43 
44 
(±2) 
46 
(±2) 
51 
(±2) 
58 
(±2) 
65 
(±2) 
72 
(±2) 
84 
(±2) 
 
Urine collections 
19 
Urinalysis 
X 
X 
 
 
X 
 
X 
 
X 
 
 
X 
 
X 
X 
20 
Pregnancy testing  
X 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
Affective and cognitive assessments 
21 
C-SSRS 
X 
X 
 
 
 
 
X 
 
X 
 
 
 
 
X 
 
22 
CGIC 
 
X 
 
 
 
 
X 
 
X 
 
 
 
 
X 
 
23 
Neuropsychological test battery 
 
X 
 
 
 
 
X 
 
X 
 
 
 
 
X 
 
24 
ADAS-Cog-14 
 
X 
 
 
 
 
X 
 
X 
 
 
 
 
X 
 
25 
A-IADL-Q 
 
X 
 
 
 
 
X 
 
X 
 
 
 
 
X 
 
26 
Drug dispensing 
 
X 
 
 
 
 
 
 
X 
 
 
 
 
 
 
27 
Telephone check 
 
 
X 
 
 
 
 
 
 
X 
 
 
 
 
 
28 
Concomitant medications 
X 
X 
X 
X 
X 
X 
X 
 
X 
X 
X 
X 
X 
X 
X 
29 
AE assessment 
 
X 
X 
X 
X 
X 
X 
 
X 
X 
X 
X 
X 
X 
X 
30 
Medication compliance check 
 
 
X 
X 
X 
X 
X 
 
 
X 
X 
X 
X 
X 
 
31 
Dose administration at study site 
 
X 
 
X 
X 
X 
X 
 
X 
 
X 
X 
X 
X 
 
32 
Dose administration at home 
 
 
<-----------------X--------------> 
 
  <--------------------------X----------------------> 
 
ADAS-Cog-14 = Alzheimer’s Disease Assessment Scale–cognitive subscale-14; AE = adverse event; A-IADL-Q = Amsterdam – Instrumental Activities of Daily Living 
questionnaire; APOE = apolipoprotein E; CGIC = Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC); C-SSRS = Columbia 
Suicide Severity Rating Scale; ECG = electrocardiogram; EEG = electroencephalography; EOS = end-of-study; FSH = follicle stimulating hormone; F/U = follow-up 
period; GDS = Geriatric Depression Scale; MMSE = Mini-Mental State Exam; PD = pharmacodynamics; PK = pharmacokinetics; TSH = thyroid stimulating hormone. 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 47 of 93 
EudraCT: 2019-003552-36 
 
Key for Table 1 Schedule of Assessments 
1. Informed consent must be obtained prior to the participant undergoing any study-specific 
procedures. 
2. Review all inclusion/exclusion criteria (see Section 9.3). 
3. Record demographic information, confirm ethnicity, and obtain medical history. 
4. Confirm AD diagnosis per the NIA-AA 2018 criteria for probable AD Dementia. 
5. Mini-Mental State Exam and Geriatric Depression Scale. 
6. Magnetic resonance imaging (MRI) of the brain will be performed, unless an MRI taken 
within the past 12 months is available. 
7. Complete physical examination: a thorough examination of all body systems, including 
height and weight. Weight should be measured on the same scale each time. Height 
may be measured only at screening.  
8. Brief physical examination: inquire about signs/symptoms, review of general 
appearance, and brief review of body systems, including weight. Weight should be 
measured on the same scale each time.  
9. Vital signs will include body temperature, systolic and diastolic BP, and heart rate. Vital 
signs will be collected prior to dose administration and 2 hours post dose on Days 1, 3, 
8, 15, and 29 in Treatment Period 1 and on Days 44, 46, 51, 58, 65, and 72 in Treatment 
Period 2. Vital signs will be collected at all other visits when convenient during the visit.  
10. ECG will be conducted during the screening period and on dosing days approximately 
2 hours post dose. 
11. Refer to the EEG manual for details. 
12. Genetic testing for the apolipoprotein E (APOE) gene.  
13. Screening labs, including TSH, hemoglobin A1c (HbA1c) and viral serology.  
14. Blood chemistry (including lipid panel) and hematology: Blood should be drawn within an 
hour of urine collection. Collections on Days 22 and 65 include coagulation testing. 
15. Whole blood for follicle stimulating hormone (FSH) in women who had their last menses 
less than 24 months prior to screening. 
16. Whole blood for Future Biomedical Research (FBR) will be collected, provided the 
participant gives consent. 
17. PK/PD Sampling:  
a. Collect 1 (± 0.25) hour predose (PK and Exploratory Biomarkers) and at 2 (± 
0.25) hours post dose (PK only) on Days 1, 29, 44, and 72.  
b. Collect 1 (± 0.25) hour predose (PK and Exploratory Biomarkers) on Days 8, 
15, 22, 51, 58 and 65. 
c. Collect once (PK and Exploratory Biomarkers) on Day 84 (follow-up visit). 
Exploratory Biomarkers 
Collect plasma for Exploratory Biomarkers predose at each visit where plasma for PK 
is collected. 
18. Participants will undergo lumbar puncture (LP) as part of screening after all other 
eligibility criteria have been met and again at the end of each treatment period. During 
Treatment Period 1, final LP should be performed on Day 29 prior to dosing (or on Days 
25 to 28 prior to dosing, if needed for scheduling purposes); during Treatment Period 2, 
the final LP should be performed on Day 72 prior to dosing (or on Days 68 to 71 prior to 
dosing, if needed for scheduling purposes). If adequate volume is available, CSF will be 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 48 of 93 
EudraCT: 2019-003552-36 
 
stored for future evaluation of biomarkers of target engagement or disease modification. 
See Section 11.5 for details. 
19. Urine should not be first morning void.  
20. For post-menopausal women, aged < 60 years, with last menses within the preceding 
24 months. The urine pregnancy test will be performed at the end of the screening 
period (within 24 hours of dosing on Day 1) and on Day 72. The pregnancy test must be 
negative prior to dosing. 
21. C-SSRS (“Screening” version) will be administered during screening and “Since-Last-
Visit” version on Days 1, 29, 44, and 72. 
22. The ADCS-CGIC will be conducted on Days 1, 29, 44, and 72. 
23. The NTB (CFT, COWAT, TMT Parts A & B, and VMDS) will be conducted during 
screening, and on Days 1, 29, 44, and 72. 
24. The ADAS-Cog-14 version A will be conducted during screening, on Day 1, and Day 29; 
version B will be conducted on Day 44 and Day 72. 
25. The A-IADL-Q will be conducted during screening, prior to the first dose on Day 1, and 
on Days 29, 44, and 72. 
26. Study drug will be dispensed on the first day of Treatment Period 1 (Day 1) and on the 
first day of Treatment Period 2 (Day 44). 
27. On Days 8 and 46, the participant and/or study partner will be called via telephone for a 
wellness check, including questions about concomitant medications and any AEs. 
28. All concomitant medications will be recorded from screening through the EOS visit. 
29. During screening (after consent), only SAEs related to a study-specific procedure will be 
collected. For all related AEs of moderate or severe intensity that are ongoing at the end 
of the study, follow-up will continue until one of the following has been met: the event 
has resolved to baseline severity; the event is assessed as stable by the Investigator; 
the patient is lost to follow-up; or the patient withdraws consent. 
30. Participant must bring all remaining study drug to each study site visit to verify how many 
tablets of study drug have been taken. 
31. Dosing on study site days will be administered by the study site staff. The dose may be 
administered with or without food. 
32. Dosing on non-study site days will be administered at home. The dose may be 
administered with or without food. 
 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 49 of 93 
EudraCT: 2019-003552-36 
 
10.2 Visit Specific Procedures 
10.2.1 Visit 1 / Screening 
Screening must be performed within 42 days prior to Baseline (Day 1). The following 
procedures will be performed at the Screening visit: 
 
Obtain signed Informed Consent Form from both participant and caregiver/study 
partner. 
 
Evaluate participant eligibility against study inclusion/exclusion criteria (Section 9.3), 
including administration of the Mini-Mental State Exam (MMSE) and Geriatric 
Depression Scale (GDS).  
 
Record demographic information, confirm ethnicity, and obtain medical history. 
 
Confirm diagnosis per the NIA-AA 2018 criteria for probable AD Dementia. 
 
Perform MRI, unless an MRI taken within the past 12 months is available (see 
Section 13.1.9 for details). 
 
Perform complete physical examination (see Section 13.1.3 for details). 
 
Measure and record vital signs (see Section 13.1.4 for details). 
 
Perform 12-lead ECG (see Section 13.1.8 for details). 
 
Draw blood and prepare samples for APOE status. APOE genotype is associated 
with the risk and age of onset of AD. Blood samples (approximately 10 mL) to 
perform this testing will be collected and will be used to further understanding of 
response to CT1812. The genotyping is mandatory for participation in the study and 
the results will not be revealed to the Investigator, participant, and caregiver/study 
partner.  
 Draw blood and prepare samples for the following: serum chemistry (including lipid 
panel), hematology; viral serology; HbA1c in known diabetics; and TSH. FSH in 
women who had their last menses less than 24 months prior to screening and who 
are not surgically sterile (see Section 13.1.5 for details). Abnormal results at 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 50 of 93 
EudraCT: 2019-003552-36 
 
screening will exclude a participant unless the Investigator is aware of a specific 
reason that can explain the abnormality (e.g., elevated CPK 24 hours after 
strenuous exercise). If an abnormal lab remains abnormal on repeat, the participant 
will be excluded. 
 Exploratory Biomarkers only, to be collected with other blood work. 
 
Optional whole blood sample collection for future biomedical research (FBR), 
including potential genetic analyses, if the participant gave specific consent (see 
Section 11.3.1). 
 
Collect urine sample for urinalysis (see Section 13.1.5 for details). 
 
Collect urine sample for β-HCG pregnancy test for post-menopausal women, aged < 60 
years, with last menses less than 24 months. Pregnancy test must be negative prior to 
dosing. 
 
Administer C-SSRS (see Section 13.1.7 for details). 
 
Record concomitant medications. 
 
Once screening results indicate participant is eligible for the study, the participant 
should undergo LP at least 24 hours before the Baseline/Day 1 visit (see Section 
11.5 for details). 
 
If eligible, schedule participant to return to the study site on Day 1 to initiate 
treatment. 
10.2.2 Visit 2 / Study Day 1 – Baseline 
The following baseline procedures will be conducted on Day 1: 
Predose assessments  
 
Confirmation of eligibility from the Sponsor; confirm continued eligibility prior to 
dosing. 
 
Perform complete physical examination (see Section 13.1.3 for details).  
 
Measure and record vital signs at predose (see Section 13.1.4 for details). 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 51 of 93 
EudraCT: 2019-003552-36 
 
 
Administer NTB, affective and cognitive assessments, ADCS-CGIC, and the 
A-IADL-Q (see Section 12.1 for details). 
 
Draw blood and prepare sample for serum chemistry and hematology (see Section 
13.1.5 for details). 
 
Collect blood samples for PK and exploratory biomarker analysis at 1 ± 0.25-hour 
predose and at 2 (± 0.25) hours postdose (PK only).  
 
Collect urine samples for urinalysis (see Section 13.1.5 for details). 
 
Record any new medical conditions, AEs, or changes in medications since 
screening. 
 
Perform EEG (see Section 12.2 for details). 
 
Observe the participant self-administer the study drug (or observe the study 
partner administer the study drug to the participant). The study drug may be 
administered with or without food. Confirm that the participant can swallow the 
study drug without difficulty. 
Postdose assessments 
 
Administer C-SSRS “Since-Last-Visit” version (see Section 13.1.7). 
 
Administer ECG approximately 2 hours postdose. ECGs will be recorded using a 
digital ECG to provide machine-generated interval measurements.  
 
Dispense study drug supply and instructions for at home dosing. 
  
10.2.3 Visit 3 / Study Day 3 – Telephone Wellness Check 
The participant and/or study partner will be called via telephone for a wellness check. 
 
Ask participant and/or study partner if any new concomitant medications were 
taken since the previous visit and record them in the case report form (CRF). 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 52 of 93 
EudraCT: 2019-003552-36 
 
 
Ask participant and/or study partner if any AEs had occurred since the previous 
visit and record them in the CRF. 
 
Instruct participant to hold the Day 8 dose and return to the study site for Visit 4.  
 
10.2.4 Visit 4 / Study Day 8 
The participant will return to the study site. 
Predose assessments  
 
Conduct drug accountability. 
 
Perform brief physical examination (see Section 13.1.3 for details). 
 
Measure and record vital signs at predose (see Section 13.1.4 for details). 
 
Draw blood and prepare sample for serum chemistry and hematology (see Section 
13.1.5 for details). 
 
Collect blood samples for PK and exploratory biomarker analysis at 1 ± 0.25-hour 
predose.  
 
Administer Day 8 dose with or without food. 
Postdose assessments  
 
Record any new medical conditions, AEs, or changes in medications since the 
previous visit. 
 
Instruct participant to hold the Day 15 dose and return to the study site for Visit 5.  
10.2.5 Visit 5 / Study Day 15 
The participant will return to the study site. 
Predose assessments  
 
Conduct drug accountability. 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 53 of 93 
EudraCT: 2019-003552-36 
 
 
Perform brief physical examination (see Section 13.1.3 for details). 
 
Measure and record vital signs (see Section 13.1.4 for details). 
 
Draw blood and prepare sample for serum chemistry and hematology (see 
Section 13.1.5 for details). 
 
Collect blood samples for PK and exploratory biomarker analysis at 1 ± 0.25-hour 
predose. 
 
Collect urine samples for urinalysis (see Section 13.1.5 for details). 
 
Administer Day 15 dose with or without food. 
Postdose assessments  
 
Record any new medical conditions, AEs, or changes in medications since the 
previous visit. 
 
Perform 12-lead ECG (see Section 13.1.8 for details). 
 
Instruct participant to hold the Day 22 dose and return to the study site for Visit 6.  
 
10.2.6  Visit 6 / Study Day 22 
Predose assessments  
 
Conduct drug accountability. 
 
Perform brief physical examination (see Section 13.1.3 for details). 
 
Measure and record vital signs at predose (see Section 13.1.4 for details). 
 
Draw blood and prepare sample for serum chemistry and hematology, including 
coagulation (see Section 13.1.5 for details). 
 
Collect blood samples for PK and exploratory biomarker analysis at 1 ± 0.25-hour 
predose.  

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 54 of 93 
EudraCT: 2019-003552-36 
 
 
Administer Day 22 dose with or without food. 
Postdose assessments  
 
Record any AEs. 
 
Record any new medical conditions, AEs, or changes in medications since the 
previous visit. 
 
Instruct participant to hold the Day 29 dose and return to the study site for Visit 7.  
 
10.2.7 Visit 7 / Study Day 29 (+/- 2 days) 
The participant will return to the study site. 
Predose assessments  
 
Drug accountability is completed. 
 
Administer C-SSRS “Since-Last-Visit” version postdose (see Section 13.1.7). 
 
Perform brief physical examination (see Section 13.1.3 for details). 
 
Measure and record vital signs at predose (see Section 13.1.4 for details). 
 
Administer CSSR, CGIC, NTB, ADAS-COG-14, and A-IADL-Q assessments (see 
Section 12.1 for details).   
 
Draw blood and prepare sample for serum chemistry and hematology (see Section 
13.1.5 for details). 
 
Collect blood samples for PK and exploratory biomarker analysis at 1 (± 0.25) hour 
predose and 2, (± 0.25) hours postdose (PK only). 
 
Collect urine samples for urinalysis (see Section 13.1.5 for details). 
 
Record any new medical conditions, AEs, or changes in medications since the 
previous visit. 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 55 of 93 
EudraCT: 2019-003552-36 
 
 
Perform EEG (see Section 12.2 for details). 
 
Perform the LP procedure (see Section 11.5 for details). 
 
Administer last dose of study drug with or without food. 
The assessments for day 29 may be split over two days (e.g., EEG and LP split from safety 
assessments, ECG, PK and cognitive assessments). 
10.2.8 Days 30 to 43 – Washout Period 
Participants will be instructed to return to study site for the Day 44 visit. 
 
 
10.2.9 Visit 8 / Study Day 44  
The participant will return to the study site and a new informed consent pertaining to the 
Treatment Period 2 will be obtained. 
The assessments for Treatment Period 1 and Treatment Period 2 are identical, except a brief 
physical examination (not a complete physical examination) will be performed in the second 
treatment period. 
Predose assessments  
 
Confirmation of eligibility from the Sponsor; confirm continued eligibility prior to 
dosing. 
 
Perform brief physical examination (see Section 13.1.3 for details).  
 
Measure and record vital signs at predose (see Section 13.1.4 for details). 
 
Administer CSSR, CGIC, NTB, ADAS-COG-14, and A-IADL-Q assessments (see 
Section 12.1 for details).  Draw blood and prepare sample for serum chemistry and 
hematology (see Section 13.1.5 for details). 
 
Collect blood samples for PK and exploratory biomarker analysis at 1 ± 0.25-hour 
predose and at 2, (± 0.25) hours postdose (PK only).  
 
Collect urine samples for urinalysis (see Section 13.1.5 for details). 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 56 of 93 
EudraCT: 2019-003552-36 
 
 
Record any new medical conditions, AEs, or changes in medications since the 
Screening visit. 
 
Perform EEG (see Section 12.2 for details). 
 
Administer Day 44 dose with or without food. 
Postdose assessments 
 
Administer C-SSRS “Since-Last-Visit” version (see Section 13.1.7). 
 
Administer ECG approximately 2 hours postdose. ECGs will be recorded using a 
digital ECG to provide machine-generated interval measurements.  
 
Dispense study drug supply and instructions for at home dosing.  
 
Instruct participant to NOT take the dose at home on the day of a study site visit. 
Explain that the study site staff will administer the study drug at the study site. 
 
10.2.10 
Visit 9 / Study Day 46 – Telephone Wellness Check 
The participant and/or study partner will be called via telephone for a wellness check. 
 
Ask participant and/or study partner if any new concomitant medications were 
taken since the previous visit and record them in the case report form (CRF). 
 
Ask participant and/or study partner if any AEs had occurred since the previous 
visit and record them in the CRF. 
 
Instruct the participant to hold the dose for Study Day 51 and return to the study 
site for Visit 10.  
 
10.2.11 
Visit 10 / Study Day 51 
The participant will return to the study site. 
Predose assessments  

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 57 of 93 
EudraCT: 2019-003552-36 
 
 
Conduct drug accountability. 
 
Perform brief physical examination (see Section 13.1.3 for details). 
 
Measure and record vital signs at predose (see Section 13.1.4 for details). 
 
Draw blood and prepare sample for serum chemistry and hematology (see 
Section 13.1.5 for details). 
 
Collect blood samples for PK and exploratory biomarker analysis at 1 ± 0.25-hour 
predose.  
 
Perform 12-lead ECG (see Section 13.1.8 for details).  ECGs will be recorded 
using a digital ECG to provide machine-generated interval measurements. 
 
Administer Day 51 dose with or without food. 
Postdose assessments  
 
Record any new medical conditions, AEs, or changes in medications since the 
previous visit. 
 
Instruct participant to hold the Day 58 dose and return to the study site for Visit 58.  
 
10.2.12 
Visit 11 / Study Day 58 
The participant will return to the study site. 
Predose assessments  
 
Conduct drug accountability. 
 
Perform brief physical examination (see Section 13.1.3 for details). 
 
Measure and record vital signs (see Section 13.1.4 for details). 
 
Draw blood and prepare sample for serum chemistry and hematology (see 
Section 13.1.5 for details). 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 58 of 93 
EudraCT: 2019-003552-36 
 
 
Collect blood samples for PK and exploratory biomarker analysis at 1 ± 0.25-hour 
predose. 
 
Collect urine samples for urinalysis (see Section 13.1.5 for details). 
 
Administer Day 58 dose with or without food. 
Postdose assessments  
 
Record any new medical conditions, AEs, or changes in medications since the 
previous visit. 
 
Instruct participant to hold the Day 65 dose and return to the study site for Visit 12.  
 
10.2.13 
Visit 12 / Study Day 65 
Predose assessments  
 
Conduct drug accountability. 
 
Perform brief physical examination (see Section 13.1.3 for details). 
 
Measure and record vital signs at predose (see Section 13.1.4 for details). 
 
Draw blood and prepare sample for serum chemistry and hematology, including 
coagulation (see Section 13.1.5 for details). 
 
Collect blood samples for PK and exploratory biomarker analysis at 1 ± 0.25-hour 
predose.  
 
Administer Day 65 dose with or without food. 
Postdose assessments  
 
Record any new medical conditions, AEs, or changes in medications since the 
previous visit. 
 
Instruct participant to hold the Day 72 dose and return to the study site for Visit 13.  

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 59 of 93 
EudraCT: 2019-003552-36 
 
 
10.2.14 
Visit 13 / Study Day 72 (+/- 2 days) 
The participant will return to the study site. 
The assessments for day 72 may be split over two days (e.g., EEG and LP split from safety 
assessments, ECG, PK and cognitive assessments). 
Predose assessments  
 
Drug accountability is completed. 
 
Administer C-SSRS “Since-Last-Visit” version postdose (see Section 13.1.7). 
 
Perform brief physical examination (see Section 13.1.3 for details). 
 
Measure and record vital signs at predose (see Section 13.1.4 for details). 
 
Administer CSSR, CGIC, NTB, ADAS-COG-14, and A-IADL-Q assessments (see 
Section 12.1 for details).  Draw blood and prepare sample for serum chemistry and 
hematology (see Section 13.1.5 for details). 
 
Collect blood samples for PK and exploratory biomarker analysis at 1 (± 0.25) hour 
predose and 2, (± 0.25) hours postdose (PK only). 
 
Collect urine samples for urinalysis (see Section 13.1.5 for details). 
 
Collect urine sample for β-HCG pregnancy test for post-menopausal women, aged 
< 60 years, with last menses less than 24 months. 
 
Record any new medical conditions, AEs, or changes in medications since the 
previous visit. 
 
Perform EEG (see Section 12.2 for details). 
 
Perform the LP procedure (see Section 11.5 for details). 
 
Administer last dose of study drug with or without food. 
Postdose Assessments 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 60 of 93 
EudraCT: 2019-003552-36 
 
 
Participant is reminded to return for Visit 14 / Study Day 84 / EOS visit. 
10.2.15 
Visit 14 / Study Day 84 / End-of-Study Visit 
The following procedures will be conducted on Day 84 / EOS Visit:  
 
Perform complete physical examination (see Section 13.1.3 for details). 
 
Measure and record vital signs (see Section 13.1.4 for details). 
 
Draw blood and prepare sample for serum chemistry and hematology (see Section 13.1.5 
for details). 
 
Collect a blood sample for PK and exploratory biomarker analysis (only 1 collection). 
 
Collect urine samples for urinalysis (see section 13.1.5) 
 
Record any new medical conditions and AEs. 
 
Perform EEG (see Section 12.2 for details). 
 
Record ECG (see Section 13.1.8 for details). 
 
Record any AEs. 
 
Record changes in medications. 
 
10.3 Concomitant Medications and Other Restrictions 
All medications mentioned in the exclusion criteria (Section 9.3) are expressly prohibited at any 
time during the study. Exceptions to the list of excluded medications may be made on a case-
by-case basis if discussed and approved by the Medical Monitor in advance. Intake of drugs or 
substances potentially involved in clinically significant CYP3A4 or P-gp mediated drug 
interactions with CT1812, within 4 weeks or 5 half-lives of the interacting drug prior to 
administration of CT1812 and throughout the study are prohibited. Grapefruit juice should be 
avoided in the 2 weeks prior to dosing and throughout the study. See Appendix A for a list of 
these prohibited substances. 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 61 of 93 
EudraCT: 2019-003552-36 
 
Participants may be on stable doses (at least 30 days prior to screening) of an 
acetylcholinesterase inhibitor and/or memantine and continue these medications during the 
study. Participants may be on a stable dose (at least 60 days prior to screening) of an SSRI 
antidepressant and may continue this medication during the study. 
11 SAMPLE COLLECTION 
11.1 Volume of Blood Collected 
The total volume of blood collected from each participant during this study will be up to 360 mL. 
11.2 Blood Sampling for PK and Exploratory Biomarkers 
Blood samples for the measurement of plasma CT1812 levels and exploratory biomarkers will 
be drawn at the following times during the study: 
 
Day -42 to-1 Exploratory Biomarkers only, to be collected with other blood work. 
 
Days 8, 15, 22, 51, 58, and 65 collect 1 (± 0.25) hour predose only. 
 
Days 1, 29, 44, and 72 collect 1 (± 0.25) hour predose (PK and Exploratory Biomarkers) 
and 2 (± 0.25) hours postdose (PK only). 
 
Day 84 (follow-up visit): PK and Exploratory Biomarkers. 
Refer to Laboratory Manual for collection procedures and sampling handling. 
11.3 Handling, Shipping, Storage, and Analysis of Blood Samples 
Please refer to the Laboratory Procedures Manual for the processing of blood samples for PK 
and biomarker analyses. 
11.3.1 Samples for Future Biomedical Research (FBR) 
Specimens obtained for Future Biomedical Research (FBR) will be collected, tracked in a 
manner consistent with Good Clinical Practice by a quality-controlled, auditable, and 
appropriately validated laboratory information management system, to ensure compliance with 
data confidentiality as well as adherence to authorized use of specimens as specified in this 
protocol and in the Informed Consent Form.  

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 62 of 93 
EudraCT: 2019-003552-36 
 
Participant blood specimens collected during this study may be stored for up to 15 years and 
used to further the knowledge of CT1812. A whole blood sample (approximately 10 mL) for 
future biomedical research will be collected during screening from participants who consent to 
have this specimen drawn. Research performed on this sample may include genetic analyses 
(e.g., DNA, gene expression profiling [ribonucleic acid], proteomics, metabolomics, or other 
analytes). Banked blood specimens may be used in the future to determine whether certain 
genotypes are correlated with the safety or efficacy of CT1812 or to answer emerging research 
questions not described elsewhere in the protocol.  
Participants in this study will not be identified by name in CRFs, study-related forms, study 
reports, or any related publications and this de-identification applies to all FBR specimens. 
Consistent with all patient information, information related to FBR specimens is confidential and 
may only be disclosed to third parties as permitted by the Informed Consent Form signed by the 
patient, unless permitted or required by law. 
Data derived from FBR specimen analysis on individual participants will generally not be 
provided to study Investigators unless a request for research use is granted.  
After collection at the site, de-identified specimens obtained for FBR will be transferred to 
Cognition Therapeutics and stored in a secure, long-term storage facility at -80° C for up to 15 
years. After 15 years, the samples will be destroyed, and archived information will be discarded 
per local/country regulation. Sampling procedures, storage conditions, and shipment 
instructions are provided to the sites in the separate laboratory procedures manual.  
Data generated from de-identified FBR specimens will be available for inspection upon request 
by representatives of national and local health authorities, and monitors, representatives, and 
collaborators, as appropriate. 
Samples of de-identified FBR specimens, genetic research data and associated clinical data 
derived from the de-identified FBR samples may be shared with researchers who are not 
participating in the study or submitted to government or other health research databases for 
sharing with other researchers for the purpose of better understanding Alzheimer’s disease 
and/or the study drug and/or other treatments. 
The Investigator should document whether or not the participant has given consent to 
participate by completing the FBR Sample Informed Consent. 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 63 of 93 
EudraCT: 2019-003552-36 
 
In the event of death or loss of competence of a participant who is participating in the Research, 
the participant’s specimen and data will continue to be used unless permission to use the 
de-identified FBR specimens is withdrawn. 
11.4 Pharmacokinetic Endpoints 
The following CT1812 pharmacokinetic assessments will be made based on serial predose 
concentrations in plasma and CSF: 
 
CT1812 CSF/plasma concentration ratio (end-of-study [EOS] only). 
 
Changes in predose CT1812 plasma concentrations.  
 
Plasma CT1812 metabolites. 
11.5 Cerebrospinal Fluid  
11.5.1 Collection 
Cerebrospinal fluid (CSF) is being collected at screening, Day 29, and Day 72 in this study to 
evaluate CSF concentrations of CT1812 following repeated dosing of CT1812 and potential 
effects on CSF biomarkers (abeta, tau, phospho-tau, NFL, neurogranin, synaptotagmin, 
SNAP25, or other exploratory biomarkers).  
A qualified physician will perform the LPs to collect CSF. Before commencing the LP, the 
clinician will ensure that there are no contraindications to the procedure. Diagnostic confirmation 
by additional 2 mL CSF sample will be collected at the screening LP. 
Samples of CSF collected at each timepoint should be sent to a local lab for cell counts (white 
blood cells and red blood cells, with differential if either of the counts is abnormal), CSF protein, 
and CSF glucose. If abnormalities at screening are observed, they should be discussed with the 
Medical Monitor before randomizing the participant. 
The Investigator may in the event of a failed LP elect attempt a repeat LP under fluoroscopy or 
CT scan or to obtain the assistance of an anesthesiologist, if these options are available at their 
IRB approved facility. Should the screening LP be unsuccessful, this would not preclude 
participation in the study, sub sequentially scheduled LPs unless there are contraindications 
based on the screening attempt. 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 64 of 93 
EudraCT: 2019-003552-36 
 
11.5.2 Timing of CSF Collection 
Samples of CSF will be collected via LP during screening with a minimum of 24 hours before 
the Baseline visit and predose on Days 29 and 72. Regardless of which day the LP is 
performed, cognitive testing for that day should be completed prior to the LP, which should be 
followed by study drug dosing for that day.  
11.5.3 Volume of CSF Collected 
The volume of CSF collected from each participant during this study will be approximately 45 
mL, (15 mL at each of the specified timepoints). 
11.5.4 Handling, Shipping, Storage and Analysis of CSF 
Please refer to the Laboratory Procedures Manual for the handling of CSF samples. Participant 
CSF specimens collected during this study may be stored for up to 15 years and used to further 
the knowledge of CT1812. 
12 EFFICACY ASSESSMENTS 
12.1 Affective and Cognitive Measures 
12.1.1 Alzheimer's Disease Assessment Scale-cognitive subscale 
The Alzheimer's Disease Assessment Scale (ADAS), a rating instrument, was developed in the 
early 1980s; it was designed specifically to evaluate the severity of cognitive and noncognitive 
behavioral dysfunctions characteristic of persons with Alzheimer's disease (Rosen 1984). The 
ADAS-cog subscale (ADAS-cog) consists of 11 tasks, which assess multiple cognitive domains, 
including memory, language, praxis, and orientation; its primary purpose is to be an index of 
global cognition in response to antidementia therapies. The ADAS Cog-14 includes the 11 tasks 
of the ADAS-Cog, plus delayed word recall, maze, and digit cancellation tasks (Kueper 2018). 
12.1.2 Geriatric Depression Scale 
The GDS is a depression screening assessment designed to identify depression in the elderly 
(Sheikh and Yesavage 1986). The short-form 15-item questionnaire with Yes and No answers 
queries participant’s energy, attitude toward life, mood, etc. Participant eligible for this study 
must not have a score about 6 out of 15. Often symptoms of depression can mask or mimic 
some symptoms of Alzheimer’s disease, therefore it is important to rule out participation of 
those who may be suffering from acute depression.  

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 65 of 93 
EudraCT: 2019-003552-36 
 
12.1.3 Mini-Mental State Exam 
The Mini-Mental State Exam (MMSE) (Folstein et al. 1975) is a brief, screening instrument often 
used in clinical studies to assess dementia severity. The MMSE assess several aspects of 
memory and cognitive functioning including orientation, attention, concentration, 
comprehension, recall, and praxis. The total possible score is 30, with high scores indicating 
less impairment.  
12.1.4 Neuropsychological Test Battery (NTB) 
NTB will consist of the CFT, COWAT, TMT Parts A & B, and VMDS. 
12.1.5  Alzheimer’s Disease Cooperative Study -Clinical Global Impression of Change 
The Alzheimer’s Disease Cooperative Study – Clinical Global Impression of Change (ADCS-
CGIC) was developed by the Alzheimer’s Disease Cooperative study (ADCS) (Schneider et al 
1997). The scale consists of a format with which a clinician may address clinically relevant 
overall change, including 15 areas under the domains of cognition, behavior, and social and 
daily functioning. The rater, at baseline, interviews the subject and study partner, using a form 
that comprehensively lists relevant symptoms potentially useful in judging change, and makes 
notes for future reference. There are few requirements to fulfill during the interview, but clinical 
assessment of mental status is to be made. By allowing raters to use the forms in an 
unstructured manner, this scale may facilitate clinical judgments with face validity. At follow-up 
visits, the clinician uses a similar set of forms to re-interview the patient and caregiver/study 
partner. The ADCS-CGIC rating is made on a 7-point scale similar to other global change 
scales, where a higher score indicates marked improvement. The ADCS-CGIC value is a 
measure of the change from baseline and therefore the algebraic change from baseline is not 
calculated for the ADCS-CGIC. The ADCS-CGIC will be completed by an independent rater (not 
the rater completing the cognitive or other assessments) where available at the site. 
12.1.6 Amsterdam Instrumental Activity of Daily Living Questionnaire 
The A-IADL-Q is an adaptive and computerized questionnaire designed to assess impairments 
in instrumental activities of daily living (IADL) in (early) dementia. The questionnaire is 
completed by a caregiver, such as a relative or friend. 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 66 of 93 
EudraCT: 2019-003552-36 
 
12.2. Other: Pharmacodynamic Assessments 
Plasma, and CSF will be stored for future evaluation of biomarkers of target engagement or 
disease modification. Specimens collected during this study may be stored for up to 15 years 
and used to further the knowledge of CT1812. 
12.2 EEG Recordings 
EEGs will be recorded on OSG digital equipment (BrainRT™; OSG BV, Rumst, Belgium); A-D 
precision (Analog to digital conversion) 20-bit, sample frequency 500 Hz, AgCl-electrodes, 
recording montage- Fz, hardware filters (0.27 – 100 Hz). EEG data in patients will be obtained 
during a 15-minute task free session with closed eyes. An EEG assessment will be conducted 
at Day 1 and at Day 29 of Treatment Period 1, and at Day 44 and 72 (Day 1 and Day 29 of 
Treatment Period 2) of the study (Table 1). Twenty-one (21) channels of the standard 10-20 
system will be recorded: Fp2 / Fp1, F8 / F7, F4/ F3, A2 / A1, T4 / T3, C4 / C3, T6 / T5, P4 / P3, 
O2 / O1, Fz, Cz, Pz, an ECG- and a respiration channel. Raw data are recorded using a 
montage with Fz as the common reference electrode. Electrode impedance will be checked 
before and after the recording and is kept below 5 KOhm. The following online filter settings are 
used: high pass 0.16 Hz, low pass 70 Hz, no notch filter. A sample frequency of 500 Hz and 
analog to digital conversion precision of 12 bit will be used. The recording is carefully monitored 
by an experienced EEG technician to minimize artefacts and to prevent drowsiness.  
13 Safety Assessments 
13.1.1 Safety Oversight 
A study safety monitoring committee will oversee the safety of the study. This committee will 
include the study director, the Sponsor’s Medical Monitor, and the site’s Principal Investigator. 
Safety data (lab reports, AEs) will be provided to the safety committee to review at monthyl 
intervals during the study. The committee will meet, at minimum, once quarterly to discuss study 
safety data. 
13.1.2 Adverse Events  
AEs will be captured from the start of study-related procedures at Visit 1 (including diagnostic 
assessments or signing of ICF) onward during the course of this study. Important medical 
events and conditions occurring prior to this period are not AEs; they will be captured within the 
medical chart and in the Medical History section of the Case Report Form. 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 67 of 93 
EudraCT: 2019-003552-36 
 
13.1.3 Physical Examination  
At study visits in which a complete physical examination is required, the Investigator should 
perform a thorough examination of all body systems (exception: genitourinary and reproductive 
should be symptom-directed). At study visits in which a brief physical examination is required, 
the Investigator should inquire about signs/symptoms, general appearance, eyes (pupillary 
reaction, ophthalmoscopy, eye movements), oral mucosa, heart and pulses, lungs, abdomen 
(liver/spleen), kidneys, and neurological (symptom-directed and may include mental state, 
speech, gait/posture, arm swinging, facial movements, tongue, muscle wasting (power and 
tone), coordination, reflexes, and sensation). 
Height should be measured at screening. Weight should be measured on the same scale at 
each visit. The Investigator must ensure that the scale is properly calibrated prior to study 
initiation.  
13.1.4 Vital Signs 
Vital signs will include body temperature, systolic and diastolic BP, and heart rate. Vital signs 
will be collected prior to dose administration and 2 hours post dose on Days 1, 3, 8, 15, and 29 
in Treatment Period 1 and on Days 44, 46, 51, 58, 65, and 72 in Treatment Period 2. Vital signs 
will be collected at all other visits when convenient during the visit..Blood pressure and pulse 
rate recordings will be made after the study patient has been at rest for ≥5 minutes in either a 
sitting or a semi-supine position. As part of vital signs, the participant’s weight should be 
measured. 
13.1.5 Clinical Laboratory Tests 
Hematology testing will include red blood cell count, erythrocyte mean corpuscular hemoglobin 
concentration (MCHC), erythrocyte MCV, hematocrit, hemoglobin, leukocyte count, and 
absolute counts of monocytes, neutrophils, basophils, eosinophils, and platelets. Coagulation 
testing (prothrombin time [PT/INR]) will be performed at screening and Days 22 and 65, prior to 
visits where LPs will be performed. 
Serum chemistry analyses will include glucose, calcium, albumin, total protein, sodium, 
potassium, bicarbonate, chloride, magnesium, blood urea nitrogen (BUN), creatinine, creatine 
kinase, alkaline phosphatase, ALT, AST, bilirubin, lipase, lactate dehydrogenase (LDH), and 
phosphorus as well as a complete lipid panel consisting of (total cholesterol, high‐density 
lipoprotein [HDL], low‐density lipoprotein [LDL] and triglycerides 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 68 of 93 
EudraCT: 2019-003552-36 
 
Urinalysis will include osmolality, creatinine, calcium, sodium, turbidity, color, specific gravity, 
pH, protein, glucose, ketones, bilirubin, blood, urobilinogen, nitrite, leukocytes, and microscopic 
particles. Urine should not be first morning void. Microscopic examination will be performed if 
urinalysis results are abnormal for bacteria, casts, epithelial cells, erythrocytes, or leukocytes. 
Urine should be collected within 1 hour of blood draws for hematology and chemistry panels. 
Trace protein will be considered positive. 
13.1.5.1 Screening Laboratory Tests 
The following will be performed to confirm participant eligibility at screening: 
 
Viral serology: hepatitis B antigen, anti-hepatitis C antibody and anti-HIV antibodies. 
 
FSH testing will be conducted in women who had their last menses less than 24 months 
prior to screening and who are not surgically sterile. 
 
Thyroid stimulating hormone (TSH) 
 
HbA1c will be conducted in known diabetics. 
 
Folate and B12 are optional at discretion of the Investigator if there is suspicion of 
deficiency. 
13.1.5.2 Confirmation of Postmenopausal Status 
A serum test for FSH will be done in women, aged < 60 years, who are post-menopausal with 
last menses occurring in the preceding 24 months. A urine pregnancy test will also be 
completed, and participants may not enter or continue in the study if pregnant. Additionally, 
women with an FSH test that is inconsistent with a postmenopausal state may not participate in 
the study.  
13.1.6 Acute Kidney Injury Biomarker Testing 
Acute kidney injury (AKI) is an abrupt loss of kidney function in the absence of volume depletion 
that develops within 7 days. In rat and dog toxicology studies of CT1812, dose-limiting toxicity 
consistently included hypercalcemia and microscopic findings of kidney proximal tubule 
degeneration. In dogs (the more sensitive species on the basis of exposures at the maximum 
tolerated dose [MTD] for changes in kidney function), increases in serum BUN and creatinine 
and lower urinary specific gravity were noted; each functional assessment fully recovered at all 
dose levels. Given these findings, kidney function will be monitored closely and at each point of 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 69 of 93 
EudraCT: 2019-003552-36 
 
routine chemistry and hematology testing to observe physiologic changes as well as early 
indicators of AKI. 
.  
13.1.7 Columbia Suicide Severity Rating Scale  
Consistent with FDA regulatory guidance (FDA 2012), any occurrence of suicide-related 
thoughts and behaviors will be assessed. The Columbia Suicide Severity Rating Scale 
(C-SSRS) (Posner 2011) includes suggested questions to elicit the type of information needed 
to determine if a suicide-related thought or behavior occurred. It rates an individual's degree of 
suicidal ideation on a scale, ranging from "wish to be dead" to "active suicidal ideation with 
specific plan and intent." The scale identifies behaviors that may be indicative of an individual's 
intent to commit suicide. If a suicide-related thought or behavior is identified at any time during 
the study, a thorough evaluation will be performed by a study physician and appropriate action 
undertaken. The “Screening” version will be used during screening, and the “Since-Last-Visit” 
version will be used at Visits 2, 7, 8, and 13. 
13.1.8 12-lead Electrocardiogram  
ECGs will be recorded using a digital ECG to provide machine-generated interval 
measurements.  
13.1.9 MRI 
The imaging specialist at the study site’s MRI facility is responsible for determining if a patient is 
contraindicated from having this procedure. Listed below are some common conditions that may 
preclude the participant from having MRI scans. However, this list should not be used as a 
substitute for local clinical standards of care. The ultimate decision to perform the MRI rests with 
the site radiologist, the Investigator, and the standards set by the local IRB/IEC: 
 
Participants who have a history of claustrophobia. 
 
Participants with a pacemaker, epicardial pacemaker wires, MRI-incompatible cardiac 
valve prostheses, and MRI-incompatible vascular clips less than 2 months old or 
MRI-incompatible aneurysm clips of any age. 
 
Participants with MRI-incompatible cochlear implants. 
 
Participants with spinal nerve stimulators. 
 
Participants with an infusion pump. 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 70 of 93 
EudraCT: 2019-003552-36 
 
 
Participants with metallic fragments in the eyes/orbits or in the vicinity of the brain or 
major neurovascular structures of the body. 
 
Participants with an employment history that involves exposure to welding, unless 
absence of metallic fragments is documented by X-ray examination as per institutional 
practice. 
 
Participants who have shrapnel at any place in their body. 
13.2  Adverse Events  
13.2.1 Definitions  
Adverse event  
An adverse event (AE) is any untoward medical occurrence in a participant or clinical 
investigation participant undergoing a study procedure or administration of a study drug. An AE 
can therefore be any unfavorable and unintended sign (including an abnormal laboratory 
finding), symptom, or disease temporally associated with the use of the study drug, whether or 
not considered related to the study drug. 
Related adverse event  
A related AE is an AE with a causality rating of “possible” or “probable.” 
Not related Adverse Event  
A not related AE is an AE with a causality rating of “unlikely” or “unrelated.” 
Laboratory abnormality 
A laboratory abnormality is any clinically significant laboratory abnormality suggesting a disease 
or organ toxicity and which is of a severity requiring active management (i.e., changes of dose, 
discontinuation of drug, more frequent follow-up, medical treatment or a diagnostic 
investigation). Laboratory abnormalities are also considered AEs, if clinically significant. 
Pretreatment adverse events  
A pretreatment AE is any AE occurring during the pretreatment period (between informed 
consent and initiation of a study drug).  
Post-study Adverse Event  
A post-study AE is an AE occurring up to 30 days after Treatment Period 2. 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 71 of 93 
EudraCT: 2019-003552-36 
 
Treatment-emergent Adverse Events  
Treatment-emergent adverse events (TEAEs) are all AEs occurring during the treatment periods 
or a pretreatment AE that worsens in intensity during either treatment period. 
Treatment period 
The treatment period is the period during which a participant receives the first dose through the 
last dose of study drug (CT1812 or placebo). 
Serious Adverse Event 
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires in-
patient hospitalization or prolongation of existing hospitalization, results in persistent or 
significant disability/incapacity, is a congenital anomaly/birth defect observed in any offspring of 
the participant conceived during treatment with the study drug or is an important medical event. 
See Section 14 for more details on SAEs. 
13.2.2 Collection and Rating of Adverse Events  
During the study (i.e., from the signing of the ICF through the Follow-up Visit plus 30 days for 
any SAE) all AEs, irrespective of the relatedness to the study drug, will be collected and 
reported on the Adverse Event Report Form. The seriousness criteria should not be confused 
with the intensity of the event. In case of an SAE, a Serious Adverse Event Report Form must 
be completed in the eCRF within 24 hours of identifying an SAE.  
Overdoses and medication errors in the presence of clinical consequences should be recorded 
as AEs. The clinical consequence should be reported as “[enter AE]” due to overdose.” 
13.2.2.1 Onset Date 
The onset date is the date when the first sign(s) or symptom(s) were first noted. For example, if 
the AE is an abnormal laboratory test (such as “platelets low”), the onset date is the date when 
the sample was taken. If the participant was hospitalized for meningitis, and symptoms such as 
fever, headache and nausea started the day before the hospitalization, the onset date is the day 
symptoms presented versus day of hospitalization. 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 72 of 93 
EudraCT: 2019-003552-36 
 
13.2.2.2 Assessment of Intensity 
The intensity of each AE will be rated according to the following 3-point scale: 
 
Mild:  
Awareness of signs or symptoms, but no disruption of usual activity. 
 
Moderate:  
Event sufficient to affect usual activity (disturbing). 
 
Severe:  Inability to work or perform usual activities (unacceptable). 
13.2.2.3 Relationship to Study Drug 
The causal relationship of the study drug to an AE will be rated according to the following 4-
point scale: 
 
Unrelated: Clearly and incontrovertibly due only to extraneous causes and does not 
meet criteria listed under possible or probable. 
 
Unlikely:  Does not follow a reasonable temporal sequence from administration; 
may have been produced by the participant’s clinical state or by environmental 
factors or other therapies administered. 
 
Possible:  Follows a reasonable temporal sequence from administration; may have 
been produced by the participant’s clinical state or by environmental factors or other 
therapies administered. 
 
Probable:  Clear temporal association with improvement on cessation of study drug 
or reduction in dose. Reappears upon re-challenge or follows a known pattern of 
response to the study drug. 
13.2.2.4 Action Taken  
The action taken toward the study drug in response to an AE will be listed as one of the 
following:  
 
None:   
 
No change in study drug dosage was made. 
 
Reduced:  
 
Dose of study drug was reduced. 
 
Discontinued  
The study drug was permanently stopped. 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 73 of 93 
EudraCT: 2019-003552-36 
 
13.2.2.5 Outcome of Adverse Event  
The outcome of an AE will be recorded as one of the following:  
 
Recovered:  Fully recovered or the condition has returned to the level observed at 
baseline. 
 
Recovered with sequelae:  Resulted in persistent or significant disability or incapacity; 
the nature of the sequelae should be specified. 
 
Not recovered. 
 
Death. 
13.2.3 Adverse Event Follow-up 
AEs requiring therapy must be treated with recognized standards of medical care to protect the 
health and well-being of the participant. 
Any participant who has any AE (whether serious or non-serious) or, in the Investigator’s 
opinion, clinically significant abnormal laboratory test values will be evaluated by the 
Investigator or a monitoring physician and will be treated and followed until the symptoms or 
values return to normal or acceptable levels, as judged by the Investigator and the Sponsor.  
AEs that are unresolved at the EOS visit or upon early withdrawal will be tracked at least weekly 
by site staff until resolution, for 30 days, or until the participant is lost to follow-up (defined as 
failure to respond to 3 phone messages left on separate days and 1 certified letter requesting 
follow-up).  
Participants will be instructed to inform site staff of any AEs occurring during the 30-day period 
after discharge or early withdrawal. 
Any follow-up information available at the time of the participant’s end--of-study visit will be 
included in the clinical study report. 
Any SAE that is considered to be unexpected and related to the study drug occurring after the 
EOS visit should be forwarded to the Sponsor. These cases will be handled and submitted as 
expedited reports but will not be included in the clinical study report. 
Note:  

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 74 of 93 
EudraCT: 2019-003552-36 
 
Any unanticipated serious adverse events (SAEs) that are ‘related’ should be reported to the 
National Institute on Aging within 48 hours of knowledge of the event. 
14 Serious and Other Significant Adverse Events  
14.1.1 Definition of a Serious Adverse Event 
An SAE is any untoward medical occurrence that: 
 
Results in death. Death is not an event per se but rather an outcome. Note that any 
event resulting in a fatal outcome must be fully documented and reported, including 
deaths that occur within 30 days after treatment ends and irrespective of the causal 
relationship to the study drug. 
 
Is life-threatening. Life-threatening refers to an AE in which the participant was at 
immediate risk of death at the time of the event. It does not refer to an event, which may 
have caused death, if it was more severe. 
 
Requires in-patient hospitalization or prolongation of existing hospitalization. 
Hospitalization means that the participant was admitted to hospital or that existing 
hospitalization was extended as a result of an event. Hospitalization describes a period 
of at least 24 hours. Overnight stays for observation; stays at the emergency room, or 
treatment on an outpatient basis do not constitute a hospitalization. However, medical 
judgment must always be exercised and, when in doubt, the case should be considered 
serious (i.e., if the case fulfills the criterion for a medically important event). 
Hospitalization for administrative or social purposes does not constitute an SAE. 
Hospital admissions and/or surgical operations planned before study inclusion are not 
considered AEs if the illness or disease existed before the participant were enrolled in 
the study, provided that the condition did not deteriorate during the study. 
 
Results in persistent or significant disability/incapacity. Disability/incapacity means 
a substantial disruption of a person’s ability to conduct normal life functions. If in doubt, 
the decision should be left to medical judgment by the Investigator. 
 
Is a congenital anomaly/birth defect. Any congenital anomaly or birth defect observed 
in any offspring of the participant conceived during treatment with the study drug. 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 75 of 93 
EudraCT: 2019-003552-36 
 
 
Is an important medical event. Important medical events are events that may not be 
immediately life-threatening or result in death or hospitalization but may jeopardize the 
participant or may require intervention to prevent one of the other outcomes listed in the 
definition above. Examples of important medical events include AEs that suggest a 
significant hazard, contraindication or precaution, occurrence of malignancy or 
development of drug dependency or drug abuse. Medical and scientific judgment should 
be exercised in deciding whether events qualify as medically important. 
An AE caused by an overdose or medical error is considered serious if a criterion listed in the 
definitions above is fulfilled. 
The following are not considered SAEs: 
 
A pre-existing condition that is present prior to or at the start of the study that did not 
worsen. 
 
Hospitalizations for treatment which were elective or preplanned, for a pre-existing 
condition unrelated to the indication under study that did not worsen. 
 
Admission to a hospital or other institution for general care, not associated with any 
deterioration in condition. 
14.1.2 Serious Adverse Event Reporting by the Investigator to the Sponsor 
During screening (after consent), only SAEs related to a study-specific procedure will be collected.  
Any SAE that occurs after a participant has been enrolled in the study, whether or not related to 
study drug, must be reported to the Sponsor or its designee immediately (within 24 hours).  
The procedure for reporting SAEs, regardless of causal relationship is as follows: 
- 
Within 24 hours if the investigator’s knowledge of an SAE, the site must notify the 
Sponsor or its designee by completing the AE form in the eCRF and selecting “Serious”. 
The Sponsor or its designee will be notified automatically by EDC that an SAE has been 
entered. 
- 
The initial SAE report should provide as much of the required information as is available 
at the time. The following minimum information is required for reporting an SAE: event 
verbatim term, seriousness criterion, investigator causality and an event outcome. 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 76 of 93 
EudraCT: 2019-003552-36 
 
Submission of the SAE via the eCRF should not be delayed in order to collect additional 
information to complete the form. 
The investigator should notify the local IRB/IEC of SAEs occurring at the site and other 
adverse events reports received from Sponsor or its designee in accordance with local 
procedures, if required. CRO Medical Monitor Contact Information: 
The Medical Monitor is available 24/7 for site contact.  Medical Monitor contact details will be 
provided directly to the clinical site.  
14.1.3  Handling of Follow-up Information 
Follow-up information may be required, or additional information may be received by the 
Sponsor (e.g., evolution of the SAE, other signs or symptoms, final diagnosis, final outcome, 
hospital discharge summary, or autopsy report). The same procedures and timelines as for 
initial reporting, listed above, should be followed for any follow-up information. If necessary, the 
study site will be visited to collect additional information. 
Follow-up information is required on all SAEs until one of the following criteria is satisfied: 
 
The final outcome of the case is known. 
 
The event is resolved, or the medical condition of the participant is stabilized. 
 
No further information is available. 
 
Sponsor assessment has been finalized. 
14.1.4 Reporting and Follow-up of Pregnancy 
When an Investigator becomes aware of the pregnancy of a female participant, the Investigator 
must withdraw the participant from the study and follow the pregnancy until termination or until 
the child is 1 month old. The pregnancy will be reported immediately by telephone and by faxing 
a completed Pregnancy Report to the Sponsor within 24 hours of knowledge of the event. The 
pregnancy will not be processed as an SAE; however, the Investigator should notify the 
Sponsor or the Sponsor’s agent of the outcome of the pregnancy by submitting a follow-up 
Pregnancy Report. Additionally, if the outcome of the pregnancy meets the criteria for 
immediate classification of an SAE (e.g., spontaneous or therapeutic abortion, stillbirth, neonatal 
death, or congenital anomaly), the Investigator will report the event by phone and by faxing a 
completed SAE Report Form to the Sponsor within 24 hours of knowledge of the event. 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 77 of 93 
EudraCT: 2019-003552-36 
 
14.1.5 Expedited Reporting of Serious Adverse Events  
14.1.5.1 Responsibilities 
The Sponsor is responsible for ensuring the timely reporting of SAEs to Regulatory Authorities 
and all Investigators who participate in the clinical development program of the study drug. It is 
the responsibility of the Investigator to provide the Sponsor with the case information such that 
reporting timeline demands of applicable Regulatory Authorities can be met. 
14.1.5.2 Expedited Reporting 
All AEs that are serious, unexpected, and considered related to the study drug judged by either 
Sponsor or the Investigator require expedited reporting. All available information relevant to the 
evaluation of the SAE will be reported. Serious adverse events will be considered reportable 
regardless of whether or not the study drug was used in accordance with the provisions in the 
protocol. 
Adverse events which are serious, but expected, or those which are not associated with the 
study drug will only be subject to expedited reporting if they are required to be reported to an 
authority according to national requirements.  
In addition, any unanticipated serious adverse events (SAEs) that are ‘related’ will be reported 
by the Sponsor to the United States National Institutes of Health within 48 hours of knowledge 
of the same. 
14.1.5.3 Timelines 
Fatal or life-threatening serious unexpected related cases require rapid reporting. Regulatory 
Authorities shall be notified as soon as possible but no later than 7 calendar days after first 
knowledge by the Sponsor representative, followed by as complete a report as possible within 
8 additional calendar days.  
Serious unexpected related cases that are not fatal or life-threatening must be submitted as 
soon as possible, but no later than 15 calendar days after first knowledge by the Sponsor 
representative that the case meets the minimum criteria for expedited reporting. 
It is the responsibility of the Investigator to support Sponsor activities needed to meet the 
aforementioned timelines for Regulatory Authority reporting in the event of an SAE. 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 78 of 93 
EudraCT: 2019-003552-36 
 
15 Statistical Methods 
15.1 General Overview of the Statistical Analysis Plan 
Individual data for all enrolled participants will be presented in data listings, sorted by participant 
and dosing arm. 
15.2 Sample Size Justification 
Based on the use of a two-sided one-sample (within-subject) comparison between CT1812 and 
placebo at the alpha=0.05 level of significance, a sample size of 16 participants provides 90% 
power to detect a mean difference between treatments of 2.5%.  
For the endpoint of CSF neurogranin, assuming a true within-subject SD of 129.6 pg/mL and 
based on the use of a two-sided one-sample comparison at the alpha=0.05 level of significance, 
a sample size of 16 participants provides 90% power to detect a treatment difference of 
−105 pg/mL. 
15.3 Analysis Populations 
The safety population will include all participants receiving one or more doses of study 
treatment.  
15.4 Data Analysis 
EEG Data Analysis: Five artefact-free epochs recorded in an awake state with eyes closed will 
be selected for each recording. Before analyses, the EEG recording will be referenced to a 
montage with an average reference. Spectral analyses will be conducted by Fast Fourier 
Transformation 
using 
BrainWave, 
a 
program 
by 
Professor 
Dr. 
C.J. 
Stam: 
http://home.kpn.nl/stam7883/brainwave.html. The following spectral measures will be calculated 
for each electrode: relative and absolute power in the delta (0.5 – 4Hz), theta (4 – 8 Hz), alpha 1 
(8 – 10 Hz), alpha 2 (10 – 13 Hz), and beta frequency band (13 – 30 Hz) and peak frequency. 
Global power per frequency band will be obtained by averaging spectral measures of all 
electrodes and regional power will be calculated in frontal, central, temporal and parieto-occipital 
regions. Before statistical analysis, the log transformation may be applied to normalize the 
distribution of absolute power values.  

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 79 of 93 
EudraCT: 2019-003552-36 
 
Statistical analysis: As noted in section 4.1, global theta activity (and in particular global relative 
theta power, i.e., the fraction of the total brain activity accounted for by theta wave frequency) is 
the most powerful early-phase diagnostic EEG marker in AD patients. As noted in section 5.1, a 
primary study objective of this study is to evaluate the efficacy of CT1812 in restoring synaptic 
function in participants with mild to moderate Alzheimer’s disease through the use of quantitative 
EEG, as reflected by relative theta power. Relative theta power is included in this study as a 
primary efficacy outcome measure. As noted in the synopsis and in section 15.2, for the endpoint 
of global relative theta power, the assumed within-subject standard deviation (SD) is equal to 3%. 
Based on the use of a two-sided one-sample (within-subject) comparison between CT1812 and 
placebo at the alpha=0.05 level of significance, a sample size of 16 participants provides 90% 
power to detect a mean difference between treatments of 2.5%. Because of their expected 
additional value in early AD, several additional EEG measures reflecting changes in brain activity 
will be added for exploratory purposes: relative power in alpha and beta bands, global peak 
frequency, and theta/alpha ratio. All the quantitative EEG outcome variables, including the primary 
efficacy outcome measure of global relative theta power, will be analysed using the analysis of 
variance (ANOVA) model for a 2-period, 2-treatment crossover study described by Senn (1993, 
pages 63-64).30 Comparisons between CT1812 and placebo will be made using two-sided tests 
at the alpha=0.05 level of significance. This study and the quantitative EEG measures that are 
included in it are exploratory in nature and any positive EEG efficacy findings may be expected 
to be confirmed in larger subsequent trials. For this reason, no correction for multiple comparisons 
are planned. 
All descriptive statistical analyses will be performed using SAS statistical software (Version 9.3 
or higher), unless otherwise noted. AEs will be assessed by the Investigator for severity and will 
be coded for summarization using Medical Dictionary for Regulatory Activities (MedDRA® 
Version 10.1 or higher). Concomitant medications will be coded using WHO Drug Dictionary 
(enhanced) Format C, 15 Aug 2005 or more recent updated version. 
Adverse events will be summarized by Medical Subject Headings (MeSH) Term for each dose 
group (including placebo), and the incidence compared. Laboratory measures will be 
summarized by treatment group and timepoint, both as absolute values and as change from 
baseline, with descriptive statistics summarizing each group and timepoint. Similar 
presentations will be used for vital signs, ECG interval measurements, and changes from pre-
treatment baseline. 
 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 80 of 93 
EudraCT: 2019-003552-36 
 
Analyses of PK parameters and pharmacodynamics markers:  
Standard non-parametric statistical analyses will be used to examine the relationships between 
dose and PK parameters. 
Pharmacodynamics markers in CSF and CT1812 concentrations in serum and CSF will be 
summarized using appropriate descriptive statistics. 
Additional statistical details will be provided in a prospective statistical plan. 
 
15.5 Missing, Unused and Spurious Data  
No imputation will be applied for missing data. Only non-missing values will be used for 
analyses. 
16 Study Management 
16.1 Protocol Amendment and Protocol Deviation 
16.1.1 Protocol Amendment 
Administrative amendments to the protocol will be classed as amendment of typographical 
errors, clarifications of confusing wording, and other minor modifications including but not limited 
to name, address, and contact information changes that have no impact on the safety of the 
participant or the science of the study. Administrative amendments will be submitted to the 
Institutional Review Board (IRB) for information only. The Sponsor will ensure that 
acknowledgement is received and filed. Otherwise, an amendment will be classed as a 
substantial amendment and will be submitted to the appropriate Regulatory Authorities and the 
IRB for approval. 
16.1.2 Protocol Deviations 
No deviations from the protocol are anticipated. Should a non-anticipated protocol deviation 
occur, the Sponsor must be informed as soon as possible. All deviations and the reasons for the 
deviation will be documented by the Investigator or designated staff. Reporting of protocol 
deviations to the IRB and in accordance with applicable Regulatory Authority mandates is the 
responsibility of the Investigator. 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 81 of 93 
EudraCT: 2019-003552-36 
 
16.1.3 Protocol Waivers 
The Sponsor will not grant protocol waivers for this study. 
16.2 Ethics and Regulatory Aspects 
16.2.1 Ethical Conduct of the Study and Regulatory Guidelines 
To ensure the ethical conduct of this clinical study, each Investigator is expected to conduct the 
study in accordance with the protocol; the United States IND regulations specified under 21 
CFR 11, 50, 54, 56, and 312; the International Conference on Harmonisation (ICH) Harmonised 
Tripartite Guideline for Good Clinical Practice (GCP); and the Guidelines of the Declaration of 
Helsinki. The Investigator will conduct all aspects of the study in accordance with all national, 
state and local laws of applicable Regulatory Authorities.  
The responsibilities of the Sponsor, the Medical Monitor, and the Investigator will be as defined 
in the ICH GCP consolidated guideline, and applicable regulatory requirements in the country 
where the study takes place. The Investigator is responsible for adhering to the GCP 
responsibilities of investigators, for dispensing the study drug in accordance with the approved 
protocol or a signed amendment, and for the secure storage and safe handling of study drug 
and other study materials throughout the study. 
16.2.2 Institutional Review Board and Regulatory Approval 
An Institutional Review Board (IRB) will review this study protocol and any amendments The 
IRB will also review the written participant information sheet and the Informed Consent Form 
(ICF), their updates (if any), and any written materials given to the participants. A listing of the 
membership of the IRB and the name of the committee chair(s) or IRB registry (accreditation) 
number will be documented within the Investigator File and Trial Master File of the Sponsor. 
Regulatory permission to perform the study must be obtained in accordance with applicable 
regulatory requirements. All ethics approvals must be obtained, and regulatory obligations met 
before a participant commencing any study-related procedures, including screening tests for 
eligibility. 
16.2.3 Participant and Study Partner Informed Consent 
Potential participants and his/her caregiver/study partner will be informed about the study both 
verbally and in writing. Each participant and his/her study partner will be provided with a written 
participant information sheet that has been approved by the IRB and will be given a reasonable 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 82 of 93 
EudraCT: 2019-003552-36 
 
time to consider the study and ask any questions they have regarding the study. The study 
partner will consent to providing information about the participant, managing drug 
administration, and attending all study site visits. The written participant information sheet and 
ICF must be in a language that the participant can understand.  
Only the Investigator, a medically qualified sub-investigator or a suitably qualified and trained 
authorized person may be involved in the informed consent process.  
The Investigator or suitable designee will obtain a freely given, written consent from each 
participant and his/her study partner after an appropriate explanation of the aims, methods, 
potential hazards, and any other aspects of the study that are relevant to the decision of the 
participant to participate. The Investigator will explain that the participant is completely free to 
refuse to enter the study or withdraw from it at any time, without any consequences for their 
further care and without the need to justify.  
The ICF and study partner consents must be signed and dated by the participant and study 
partner before commencing any study-related procedures, including screening tests for 
eligibility. The participant and study partner will receive copies of the written participant 
information sheet, the ICF, and study partner consent form. 
Each participant will be informed that the Sponsor’s study monitor, a Quality Assurance Auditor 
mandated by the Sponsor, or a Health Authority Inspector, in accordance with applicable 
regulatory requirements, may review his or her source records and health data. Data protection 
will be handled in compliance with national and local regulations. 
If new safety information becomes available and results in significant changes in the risk to 
benefit assessment, the written participant information sheet will be revised or updated where 
necessary. Under these circumstances, all participants (including those already being treated) 
should be informed of the new information, given a copy of the revised form, and allowed to 
reevaluate their consent to continue in the study. 
16.3 End of Study and Regulatory Notification 
The study can be terminated in part or in whole at the discretion of the FDA, an applicable 
Regulatory Authority or the Sponsor.  
At the end of the study, the IRBs and Regulatory Authorities will be notified by the Sponsor 
according to applicable regulatory requirements. 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 83 of 93 
EudraCT: 2019-003552-36 
 
16.4 Data Protection and Confidentiality 
The confidentiality of records that could identify participants should be protected, respecting the 
privacy and confidentiality rules in accordance with applicable regulatory requirement(s). 
16.5 Monitoring 
The study will be monitored to ensure that the study is conducted and documented properly 
according to the protocol, GCP, and all applicable regulatory requirements.  
On-site visits will be made at appropriate times during the study. The Sponsor’s monitors must 
have direct access to source documentation in order to check the consistency of the data 
recorded in the CRFs. 
The Investigator will make available to the Monitor all source documents, medical records, and 
source data necessary to complete CRFs. Also, the Investigator will work closely with the 
Sponsor’s monitors and as needed, provide them appropriate evidence that the conduct of the 
study is being done in accordance with applicable regulations and GCP guidelines. 
16.6 Quality Assurance and Quality Control 
The Sponsor or its designee will perform the quality assurance and quality control activities of 
this study; however, the site’s Principal Investigator is responsible for the accuracy, 
completeness, and reliability of the study data presented to the Sponsor.  
Prior to the study initiation, the Sponsor will explain the protocol, Investigator’s Brochure, and 
CRFs to Investigators. Also, the Monitor will be available to explain applicable regulations and 
answer any questions regarding the conduct of the study. 
At its discretion, the Sponsor may conduct audits as part of the implementation of quality 
assurance to ensure that the study is being conducted in compliance with the protocol, Standard 
Operating Procedures, GCP, and all applicable regulatory requirements. Audits will be 
independent of and separate from the routine monitoring and quality control functions. 
The study site may also be compelled to an inspection by a Regulatory Authority. 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 84 of 93 
EudraCT: 2019-003552-36 
 
16.7 Source Data 
Source data are defined as information in original records and certified copies of original records 
of clinical findings, observations, data, or other activities in a clinical study necessary for the 
reconstruction and evaluation of the study.  
Source documents are the original data, documents, and records. Examples include hospital 
records, laboratory reports, clinical and office charts, laboratory notes, memoranda, evaluation 
checklists, pharmacy dispensing records, recorded data from automated instruments, copies or 
transcriptions certified after verification as being accurate copies, microfiches, photographic 
negatives, microfilm or magnetic media, x-rays, other radiographic depictions or displays, and 
participant files, as well as records kept at the pharmacy, laboratories, and medico-technical 
departments involved in the clinical study. The Primary Investigator and Sponsor (or designee) 
must review all source documents for compliance with GCP. 
Study-specific data sheets may be used to document source information that would normally not 
be collected and documented in the routine management of the participant. The Investigator or 
designee must verify and sign all data sheets used for source documentation. The signed study-
specific data sheets must be stored and archived in the participant’s study records (preferably) 
or in the Investigator File. 
The Investigator will permit study-related monitoring, audit(s), IRB review(s), and regulatory 
inspection(s), with a direct access to all the required source documents and associated records. 
17 Data and Record Keeping 
17.1 Case Report Forms 
All data will be entered in a validated electronic data capture system using single data entry. 
Standard procedures (including following data review guidelines, manual clinical review based 
on participant profiles, computerized validation to produce queries, and maintenance of an audit 
file which includes all database modifications) will be followed to ensure accurate data. The 
Investigator’s clinical staff will review all data listings for outliers, data inconsistencies, and 
spelling errors. 
During the study, the Sponsor’s study monitor will make site visits to review protocol 
compliance, compare CRFs against individual participant’s medical records, assess drug 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 85 of 93 
EudraCT: 2019-003552-36 
 
accountability, and ensure that the study is being conducted according to pertinent regulatory 
requirements. 
Electronic data capture (EDC) entries will be verified with source documentation. The review of 
medical records will be performed in a manner to ensure that participant confidentiality is 
maintained. Checking the EDC for completeness and clarity and cross-checking with source 
documents is required to monitor the progress of the study. Direct access to source data is also 
required for inspections and audits and will be carried out giving due consideration to data 
protection and medical confidentiality. 
17.2 Record Keeping 
Study records and source documents need to be preserved for at least 15 years after the 
completion or discontinuation of/withdrawal from the study or 2 years after the last approval of a 
marketing application of CT1812 in an ICH region, whichever is the longest time period. The 
Sponsor will be notified prior to the planned destruction of any study related source documents. 
18 Financing and Insurance 
 
Financial aspects of the study are addressed in a separate clinical study agreement.  
The Investigator is required to have adequate current insurance to cover claims for negligence 
and/or malpractice. The Sponsor will provide insurance coverage for the clinical study as 
required by national regulations. 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 86 of 93 
EudraCT: 2019-003552-36 
 
19 Use of Data and Publication Policy 
 
Both the use of data and the publication policy are detailed within the clinical study agreement. 
The Investigator should be aware that intellectual property rights (and related matters) 
generated by the Investigator and others performing the clinical study will be pursuant to the 
terms of a clinical study agreement that will be agreed between the Institution and the Sponsor 
or designee. With respect to such rights, the Sponsor or designee will solely own all right and 
interest in any materials, data and intellectual property rights developed by the Investigator and 
others performing the clinical study described in this protocol, participant to the terms of any 
such agreement. In order to facilitate such ownership, the Investigator will be required to assign 
all such inventions either to the Institution where the study is conducted or directly to the 
Sponsor or their designee, as will be set forth in the clinical study agreement. This agreement 
will not preclude the reporting of any required data to Regulatory Authorities.

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 87 of 93 
 
 
20 References 
Benton A, Hamsher K, Sivan A. (1994) Multilingual Aphasia Examination. AJA Associates, Iowa 
City.  
Brott DA, Adler SA, Arani R, Lovick SC, Pinches M, Furlong ST. (2014) Characterization of 
renal biomarkers for use in clinical trials: biomarker evaluation in healthy volunteers. Drug Des 
Devel Ther. 8:227 – 237. 
Colclough, G. L., Brookes, M. J., Smith, S. M., & Woolrich, M. W. (2015). A symmetric 
multivariate leakage correction for MEG connectomes. Neuroimage, 117, 439-448. 
FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. 
Available at: 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractio
nsLabeling/ucm093664.htm#4 [accessed 26 Apr 2016]. 
Flockhart DA. (2007) Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana 
University School of Medicine. “http://medicine.iupui.edu/clinpharm/ddis/clinical-table”  
[accessed 17 Apr 2016]. 
Folstein MF, Folstein SE, McHugh PR. (1975) “Mini-mental state.” A practical method for 
grading the cognitive state of patients for the clinician. J Psychiatr Res. 12(13):189 -198. 
Gouw AA, Alsema AM, Tijms BM, Borta A, Scheltens P, et al. (2017) EEG spectral analysis as a 
putative early prognostic biomarker in nondemented, amyloid positive subjects. Neurobiol 
Aging. 57:133-142. 
Regensburger Verbal Fluency Test. Göttingen: Hogrefe; 2000. 
Hipp JF, Hawellek DJ, Corbetta M, Siegel M, Engel AK. Large-scale cortical correlation 
structure of spontaneous oscillatory activity. Nature neuroscience. 2012 Jun;15(6):884. 
Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, et al. (2006) AMPAR Removal Underlies 
Ab-Induced Synaptic Depression and Dendritic Spine Loss. Neuron 52:831 – 843. 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 88 of 93 
 
Izzo NJ, Staniszewski A, To L, Fa M, Teich AF, et al. (2014) Alzheimer’s therapeutics targeting 
amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is 
displaced by drug candidates that improve cognitive deficits. PLOS ONE. 9(11):e0111898. 
Izzo NJ, Xu J, Zeng C, Kirk MJ, Mozzoni K, et al. (2014) Alzheimer’s therapeutics targeting 
amyloid beta 1-42 oligomers II: sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding 
and synaptotoxicity. PLOS ONE. 9(11):e0111899. 
Kueper JK, Speechley M, Montero-Odasso M (2018). The Alzheimer's Disease Assessment 
Scale-Cognitive Subscale (ADAS-Cog): Modifications and Responsiveness in Pre-Dementia 
Populations. A Narrative Review. J Alzheimer's Dis. 63(2):423-444. 
Lacor PN, Buniel MC, Furlow PW, Sanz Clemente A, Velasco PT, et al. (2007) A Oligomer-
Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis 
for Loss of Connectivity in Alzheimer’s Disease. J Neurosci. 27(4):796 – 807. 
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR et al. (2011) The diagnosis of 
dementia due to Alzheimer’s disease: Recommendations from the National Institute of Aging-
Alzheimer’s Association workgroups on diagnostic guidelines for the diagnosis of Alzheimer’s 
Disease. Alzheim Dementia. 7;263 – 269. 
Mundt JC, Greist JH, Gelenberg AJ, Katzelnick DJ, Jefferson JW, Model JG. (2010) Feasibility 
and validation of a computer-automated Columbia-Suicide Severity Rating Scale using 
interactive voice response technology. J Psychiatr Res. 44(16):1224 – 1228. 
Mundt JC, Greist JH, Jefferson JW, Federico M, Mann JJ, & Posner K. (2013) Prediction of 
suicidal behavior in clinical research by lifetime suicidal ideation and behavior ascertained by 
the electronic Columbia-Suicide Severity Rating Scale. J Clin Psychiatry. 74(9);887 – 893. 
Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, et al. (2011) The Columbia-Suicide 
Severity Rating Scale: initial validity and internal consistency findings from three multisite 
studies with adolescents and adults. Am J Psychiatry. 168(12):1266 – 1277. 
Price RG. (1992) The role of NAG (N-acetyl-beta-D-glucosaminidase) in the diagnosis of kidney 
disease including the monitoring of nephrotoxicity. Clin Nephrol. 38 Suppl 1:S14 – 9. 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 89 of 93 
 
Rosen WG, Mohs RC, Davis KL. (1984) A new rating scale for Alzheimer's disease. Am J 
Psychiatry. 141(11):1356 – 1364. 
Rubinov, M., & Sporns, O. (2010). Complex network measures of brain connectivity: uses and 
interpretations. Neuroimage, 52(3), 1059-1069. 
Scheltens P, Hallikainen M, Grimmer T, Duning T, Gouw AA, et al. (2018). Safety, tolerability 
and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a 
randomized, double-blind, placebo-controlled phase 2a study. Alzheimer's research & therapy, 
10(1), 107. 
Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. (2007) Natural 
oligomers of the alzheimer amyloid-protein induce reversible synapse loss by modulating an 
NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 27(11):2866 – 2875. 
Sheikh JI, Yesavage JA. Geriatric Depression Scale (GDS): recent evidence and development 
of a shorter version. In: Brink TL, ed. Clinical Gerontology: A Guide to Assessment and 
Intervention. New York, NY: The Haworth Press; 1986:165-173. 
Stam, C. J. (2018).  BrainWave: A Java based application for functional connectivity and 
network analysis.  Available at: http://home.kpn.nl/stam7883/brainwave.html. [accessed 21 Feb 
2022]. 
Stam, C. J., Tewarie, P., Van Dellen, E., Van Straaten, E. C. W., Hillebrand, A., & Van 
Mieghem, P. (2014). The trees and the forest: characterization of complex brain networks with 
minimum spanning trees. International Journal of Psychophysiology, 92(3), 129-138. 
de Waal H, Stam CJ, de Haan W, van Straaten ECW, Scheltens P, and van der Flier WM, 
Young Alzheimer patients show distinct regional changes of oscillatory brain dynamics. 
Neurobiol. Aging, vol. 33, no. 5, pp. 1008.e25–31, May 2012. 
United States Food and Drug Administration. Guidance for Industry. Suicidal Ideation and 
Behavior: Prospective Assessment of Occurrence in Clinical Trials [draft guidance], August 
2012. Available at: http://www.fda.gov/downloads/Drugs/Guidances/UCM225130.pdf. [accessed 
04 Feb 2013]. 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 90 of 93 
 
Yu Y, Jin H, Holder D, Ozer JS, Villarreal S, et al. (2010) Urinary biomarkers trefoil factor 3 and 
albumin enable early detection of kidney tubular injury. Nat Biotechnol. 28(5):470-477. 
Zempel H, Luedtke J, Kumar Y, Biernat J, Dawson H, et al. (2013) Amyloid-b oligomers induce 
synaptic damage via Tau-dependent microtubule severing by TTLL6 and spastin. EMBO. 
32:2920–2937. 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 91 of 93 
 
 
 
 
21 APPENDICES 
Appendix A – Prohibited Medications - Cytochrome P450 Drug Interaction Table  
 
In addition to the medications detailed in various exclusion criteria (Section 9.3), the following 
medications are restricted within 4 weeks of screening visit and during the study. Exceptions to 
the list of excluded medications may be made on a case‐by‐case basis, if discussed and 
approved by the Sponsor’s Medical Monitor in advance. 
 
 
Antipsychotic agents. 
 
Antiepileptics. 
 
Centrally active anti‐hypertensive drugs (e.g., clonidine, l‐methyl dopa, guanidine, 
guanfacine, etc.). 
 
Sedatives. 
 
Opioids. 
 
Mood stabilizers (e.g., valproate, lithium); or benzodiazepines, with the following exception: 
Low-dose lorazepam may be used for sedation prior to MRI scan for those subjects 
requiring sedation. At the discretion of the Investigator, 0.5 mg to 1 mg may be given 
orally prior to scan with a single repeat dose given if the first dose is ineffective. No more 
than a total of 2 mg lorazepam may be used for the MRI scan. 
 
Nootropic drugs (except stable AD medications: acetylcholinesterase inhibitors and 
memantine), e.g., Gingko biloba extract. 
 
Moderate to strong inhibitors or inducers of CYP3A4. See Appendix A for a complete list of 
restricted medications. 
 
All hormonal contraceptives and hormone replacement therapies (oral, injectable, 
transdermal, or implanted). 
 
Calcium channel blockers (only diltiazem and verapamil are excluded). 
 
Coumadin® or other anticoagulant medications. 
 
Digoxin. 
 
Inability to separate dosing of CT1812 by at least 6 hours (before or after) from the 
participant’s concomitant medications that are sensitive or are narrow therapeutic index: 
substrates of CYP3A4; P‐glycoprotein (P‐gp); loperamide; vinblastine; or talinolol. 
 
Exposure to immunomodulators, anti Aβ vaccines, passive immunotherapies for AD (e.g., 
monoclonal antibodies) within the past 180 days and/or exposure to BACE inhibitors within 
the past 30 days. 
 
 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 92 of 93 
 
 
 
 
 
Below are partial listings of specific medications excluded in COG0202. Most of these 
categories are represented in exclusion criteria (see Section 9.3). This list might not be 
all-inclusive for specific categories of medications. Check with the Sponsor’s Medical Monitor if 
there are questions. 
 
Barbiturates 
 
benzylbutylbarbiturate 
butalbital 
amobarbital 
pentobarbital 
secobarbital 
sodium thiopental 
phenobarbital 
 
Benzodiazepines 
 
clonazepam 
diazepam 
estazolam 
flunitrazepam 
lorazepam 
midazolam 
nitrazepam 
oxazepam 
triazolam 
temazepam 
chlordiazepoxide 
alprazolam 
clobazam 
clorazepate 
etizolam. 
 
Nonbenzodiazepine 
hypnotics 
 
eszopiclone 
zaleplon 
zolpidem 
zopiclone 
 
Opioids 
 
tramadol 
tapentadol 
morphine 
hydromorphone 
oxymorphone 
oxycodone 
hydrocodone 
methadone 
propoxyphene 
meperidine 
fentanyl 
codeine 
carfentanil. 
 
Antipsychotics  
 
olanzapine 
clozapine 
thiothixene 
haloperidol 
fluphenazine 
prochlorperazine 
trifluoperazine 
loxapine 
quetiapine 
asenapine 
 
Other 
 
glutethimide 
sodium oxybate (Xyrem®) 
 
First-generation 
antihistamines 
 
The following should not be 
used within 24 hours of 
cognitive testing: 
 
diphenhydramine 
dimenhydrinate 
doxylamine 
promethazine 
hydroxyzine 
brompheniramine 
chlorpheniramine. 
 

Protocol # COG0202 
 
CT1812 in Alzheimer’s Disease 
FINAL Version 4.0 
 
Issue Date: February 21, 2022 
 
CONFIDENTIAL AND PROPRIETARY 
 
Page 93 of 93 
 
 
 
 
3A4,5,7 
INHIBITORS 
3A4,5,7 
INDUCERS 
CYP3A Substrates with narrow therapeutic 
range 
HIV Antivirals: 
indinavir 
nelfinavir 
ritonavir. 
 
clarithromycin 
itraconazole 
ketoconazole 
nefazodone 
erythromycin 
grapefruit juice 
verapamil 
 
suboxone 
diltiazem. 
 
carbamazepine 
efavirenz 
nevaripine 
phenobarbital 
phenytoin 
pioglitazone 
rifabutin 
rifampin 
St. John’s wort 
troglitazone. 
alfentanil 
astemizole 
cisapride 
cyclosporine 
dihydroergotamine 
ergotamine 
fentanyl 
pimozide 
quinidine 
sirolimus 
tacrolimus 
terfenadine. 
 
Sensitive P-gp Substrate: 
digoxin. 
 
 
 
Source:  
Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University 
School of Medicine (2007). "http://medicine.iupui.edu/clinpharm/ddis/clinical-table”  
Accessed: 17 Apr 2016.